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Epstein-Barr virus (EBV) is the etiological agent of infectious 
mononucleosis and is associated with various diseases such as 
Burkitt’s lymphoma, nasopharyngeal carcinoma, and post-transplant 
lymphoproliferative disorder (PTLD). In all of these diseases, the 
expression of Epstein-Barr virus nuclear antigen 1 (EBNA-1) is 
common and therefore this viral protein represents a possible 
therapeutic target. Previous studies have intimated that EBNA-1 auto-
inhibits its presentation to the immune system via the expression of a 
glycine-alanine rich domain that blocks proteasomal degradation. Thus 
to understand the expression of EBNA-1 and to evaluate the potential 
of targeting this viral antigen in the context of PTLD, we examined the 
role of glycine-alanine repeats (GAr) in EBNA-1 protein expression and 
further investigated the in vivo efficacy of an in-house produced α-
EBNA-1 T cell receptor-like monoclonal antibody (α-EBNA-1 TCR-like 
mAb) using a mouse xenograft model of PTLD. With the aim of 
translating our findings into studies relevant to humans, we developed 
and optimized an autologous humanized mouse model for future 
preclinical evaluations of the antibody.   
 
Here, we confirmed previously published data that the GAr within the 
EBNA-1 protein can indeed inhibit its synthesis, reducing its availability 
for presentation on MHC class l molecules. Despite this observation, 
xii 
 
we were able to detect the presentation of EBNA-1 peptide on EBV-
infected B lymphoblastoid cell lines (BLCL) using our in-house α-
EBNA-1 TCR-like mAb. This antibody demonstrated in vivo efficacy in 
a mouse xenograft model engrafted with BLCL to model PTLD, 
conferring delayed weight loss and prolonged survival in treated mice. 
We further elucidated the mechanisms elicited by this antibody and 
showed that α-EBNA-1 TCR-like mAb could promote early apoptosis 
and phagocytosis in vitro. 
 
We next established a humanized mouse model for the future testing of 
α-EBNA-1 TCR-like mAb. In this model, autologous BLCL was 
generated in vitro and injected into humanized mice reconstituted from 
the same donor. Using this approach, BLCL could be characterized 
and tested for binding to α-EBNA-1 TCR-like mAb in vitro prior to in 
vivo evaluations. With the employment of hydrodynamic injection of 
plasmids encoding human cytokines, we were able to augment NK 
cells reconstitution, thereby providing the option of investigating NK 
cell-mediated cytotoxicity. This autologous humanized mouse model 
not only provides the means to dissect the effector functions of α-
EBNA-1 TCR-like mAb in the presence of reconstituted human immune 
cells, it can also serve as a platform for the testing of novel therapies.  
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1.1 EBV overview 
 
EBV is a ubiquitous human gammaherpesvirus found in more than 
90% of the human population [1]. EBV establishes life-long latent 
infection in humans and is estimated to have co-evolved with primates 
for millions of years [2]. The virus was discovered by Anthony Epstein, 
Yvonne Barr, and Burt Achong based on the employment of electron 
microscopy to observe virus particles in Burkitt’s lymphoma (BL) 
biopsies [3]. Discovered in 1964, EBV was classified as the first human 
tumor virus by the World Health Organization in 1997 (International 
Agency for Research on Cancer Group I Carcinogens) [4]. 
 
EBV is a large, linear double-stranded deoxyribonucleic acid (DNA) 
virus (~172 kb) with a genome encoding more than 100 viral gene 
products [5]. The virus has a tropism for B cells and epithelial cells, and 
had been shown to transform human B cells in vitro, into immortalized 
BLCL [1, 6]. In vivo, primary EBV infection during childhood is often 
asymptomatic but can lead to the development of IM when infection 
occurs during adolescence [7]. To date, the virus is identified as the 
etiological agent of infectious mononucleosis (IM) and is associated 
with malignancies of both epithelial and lymphoid origins (Table 1.1). 
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1.1.1 EBV life cycle 
 
The lymphocryptovirus EBV is transmitted through oral secretions of 
infected individuals, infecting B cells in the oropharynx [6]  (Figure 1.1). 
The entry of EBV into the B cell is mediated through the binding of 
glycoprotein (gp350) on the viral envelope to the receptor - cluster of 
differentiation 21 (CD21) on the B cells. Upon infection, the linear EBV 
genome circularizes and forms an episomal genome, establishing 
latent infection in the memory B cell compartment (Figure 1.2) [8, 9]. In 
healthy adults, 1 to 50 EBV-infected cells per one million peripheral 
blood lymphocytes (PBL) can be found in the circulation [10]. 
Occasionally, these latently infected cells can undergo reactivation and 
lytic replication, leading to their recognition and elimination by cytotoxic 
T lymphocytes (CTLs).  
 
 
1.1.2 EBV-associated diseases  
 
Aside from IM, EBV infection is also associated with a spectrum of 
malignancies such as BL, Hodgkin’s lymphoma (HL), nasopharyngeal 
carcinoma (NPC) and PTLD. The chronicity of EBV infection is based 
on the adaptation of different latency programs in various EBV-
associated diseases; namely, latency I (in BL), latency II (in HL and 
NPC) and latency III (in IM and PTLD). While each latency program is 
characterized by a specific gene expression pattern as shown in Table 
 5 
 
1.1, EBNA-1 is the only EBV latent protein which is expressed in all 









Figure 1.2: Schematic of the EBV episome. The genome of EBV is 
approximately 172 kb. oriP is required for the replication of plasmid while 
oriLyt are the two sites for lytic replication activation. All nine latent proteins 
are illustrated: EBNA-LP, EBNA-1, EBNA-2, EBNA-3 (A, B, and C), LMP1, 
and LMP2 (A and B). Image adapted from Alexander M. Price and Micah A. 
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1.2 EBNA-1 overview  
 
The prototypic EBNA-1 protein is a 641 amino acids, 56 kDa protein 
that is expressed in both lytic and latent phases of EBV infection. 
EBNA-1 proteins from different geographical isolates of EBV are 
different in sizes due to the variation in the number of glycine-alanine, 
and thus far, five EBNA-1 subtypes have been classified based on the 
carboxy-terminus of the EBNA-1 protein [11-13].  
 
 
Published findings on EBNA-1 reported its necessity in viral replication 
and maintenance of EBV episomal DNA via initiating DNA synthesis 
and tethering of EBV episome to the host chromosomes [14-16]. 
Subsequently, based on the lack of detection of EBNA-1-specific CD8+ 
CTLs, EBNA-1 was proposed to play a role in immune processing and 
evasion [17-19]. In recent years, additional published evidence 
suggests that EBNA-1 also contributes to the oncogenic potential of 
EBV [20-23].  
 
Given the multifaceted involvements of EBNA-1 in viral DNA replication, 
immunoevasion, and oncogenesis, it is anticipated that targeting 
EBNA-1 can abrogate viral replication, inhibit host cell transformation 
and enhance immune detection. As the protein is only expressed in 
EBV-infected cells, targeting EBNA-1 provides selectivity over the non-




1.2.1 Role of EBNA-1 in viral genome maintenance  
 
EBNA-1 functions as a genome maintenance protein, mediating two 
critical processes: the initiation of viral DNA synthesis and episomal 
segregation [14-16]. As shown in Figure 1.3, the carboxy-terminus of 
EBNA-1 protein contains a DNA-binding domain which binds to two 
clusters within the oriP (origin of plasmid replication) of the viral 
episome; namely, dyad symmetry (DS) and family of repeats (FR). 
While DS serves as a site for the initiation of replication, FR functions 
as an anchor point for the binding of EBNA-1 protein to ensure equal 
partitioning of the viral episomes into daughter cells during cellular 




Figure 1.3: Schematic of WT EBNA-1 and its truncated variant 
(E1ΔGA). The WT EBNA-1 protein contains 641 amino acids (UniProt 
accession number: P03211). The C-terminal region contains the DNA 
binding domain for binding to the EBV episome. Within the WT protein, 
the GAr (solid black) occupies the positions 90 to 325 on the protein. A 
truncated variant with the deletion of GAr is denoted as E1ΔGA. 
Numbers indicated refer to the coordinates of the amino acids.   
 
 




1.2.2 Role of EBNA-1 in EBV-oncogenesis 
 
EBNA-1 is the only EBV protein that is expressed in all EBV-associated 
malignancies and this may suggest a common mechanism of EBNA-1-
induced oncogenesis. As reported by Gahn et al., EBNA-1 was found 
to interact with the viral promoter that activates the transcription of EBV 
latent genes involved in cell immortalization and transformation [27, 28]. 
Moreover, EBNA-1 expression in 293T cells promoted serum 
independence, survival [20] and upregulated reactive oxygen species 
as well as genomic instability in BL cell lines [22, 23].  
 
The protein is further implicated in the perturbation of TGF-β1 signaling 
in epithelial cells [29], dysregulating cellular functions such as cell 
proliferation and survival, all of which are the prerequisites of cancer 
development [30]. Moreover, the introduction of anti-sense EBNA-1 or 
EBNA-1-deficient viruses resulted in the failure of B cell immortalization 
[15, 31], whereas expression of EBNA-1 plasmids (in the absence of 
the whole virus) resulted in increased tumor formation and metastasis 
of murine cancer cells in vivo  [32, 33]. While direct evidence of EBNA-
1-induced oncogenesis has been forthcoming, these studies do provide 




1.2.3 Role of EBNA-1 in immunoevasion 
 
The classical major histocompatibility complex (MHC) class I antigen 
presentation pathway is intrinsic to all nucleated cells, where 
endogenous proteins destined for presentation are tagged with 
ubiquitin and targeted for degradation by the proteasome [34-36]. 
These degraded proteins, in the form of short peptides, are then 
transported into the endoplasmic reticulum via the transporter 
associated with antigen processing for subsequent loading onto 
nascent MHC class I molecules [37]. These peptide-MHC (pMHC) 
complexes are then trafficked via the secretory pathway onto the cell 
surface for presentation [38, 39]. In this regard, MHC class l antigen 
presentation is essential for immunosurveillance by presenting viral or 
tumor antigens as short peptides to CD8+ CTLs to eliminate both virus-
infected and malignant cells  [40, 41].  
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In the early 1990s, the EBNA-1 protein was proposed to play a role in 
EBV immune evasion due to the inability of researchers to isolate 
EBNA-1-specific CD8+ CTLs from EBV-seropositive individuals [19, 42, 
43]. While EBNA-1-specific CD4+ T cells and its memory subsets were 
detected [19, 44-48], it was intriguing that the endogenously expressed 
EBNA-1 protein was less recognized by the CD8+ CTLs, and was less 
immunogenic compared to other EBV latent proteins such as latent 
membrane protein 1 (LMP1) and EBNA-3 [42, 49]. Furthermore, in 
silico prediction algorithms showed that the EBNA-1 protein expressed 
fewer binding motifs for MHC class I molecules, and this seemed to 
correlate with the lack of EBNA-1-specific CD8+ CTLs detected [50].  
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With the failure to detect EBNA-1-specific CD8+ CTLs in EBV-
seropositive individuals, it was proposed that the GAr within the EBNA-
1 protein was able to hinder the ubiquitin-proteasome proteolysis 
process, thereby leading to the inefficient presentation of EBNA-1 
epitopes on MHC class I molecules  [17, 51]. The role of GAr in 
proteasomal inhibition was further enforced when the removal of GAr 
restored the presentation of EBNA-1 epitopes to CD8+ CTLs, while its 
insertion into other proteins inhibited their degradation and T cell 
recognition  [17, 18, 52]. Additionally, it was reported that the degree of 
proteasomal inhibition is dependent on the length of GAr and that 
inhibition was observed with a minimal of eight GAr [53-55].  
 
In 2004, three consecutive publications questioned the lack of 
detection for the EBNA-1-specific CD8+ CTLs and reported that EBNA-
1 protein could be presented via defective ribosomal products; in other 
words, EBNA-1 epitopes were generated through processes that 
involved its synthesis rather than a result of its degradation [56-58]. 
These observations altered the paradigm of GAr in the antigen 
presentation of EBNA-1. While the proposed mechanisms of GAr in 
inhibiting its own presentation are not mutually exclusive, accumulating 
evidence from the recent years supported the argument that 
presentation of EBNA-1 originates from its non-functional products of 
the protein translational machinery [59-63].  
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1.3 PTLD overview 
 
PTLD is one of the EBV-associated diseases which arises in solid 
organ or allogeneic hematopoietic stem cell transplant recipients. As a 
heterogeneous group of diseases, the spectrum of PTLD ranges from 
B cell hyperplasia to B cell lymphoma (Table 1.2). The incidence of 
PTLD varies from 1% to 20%, depending on the type of the organ 
transplanted, recipient’s age and the intensity of immunosuppressants 
administered [64-69]. Even though the overall incidence of PTLD is low, 
it is a potentially life-threatening disease with high mortality rates [70].  
 
The association between PTLD and EBV was made based upon the 
observation that EBV-seronegative recipients who lacked EBV-specific 
immunity were more susceptible to PTLD development in comparison 
to EBV-seropositive recipients [71]. Evidence on EBV shedding 
preceding to PTLD development, and the elevated viral DNA load and 
proteins found in PTLD tissues further supported the involvement of 
EBV in PTLD development  [72-74].  
 
EBV-seropositive recipients are also at risk of developing PTLD 
because the administration of immunosuppressants to prevent graft 
rejection can lead to the suppression of T cell immunity, and this can 
consequently perturb the balance between T cell immunity and the 
latently EBV-infected B cells [75, 76]. As a result of 
immunosuppression, the unrestricted proliferation of EBV-infected B 
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cells accompanying the expression of a full repertoire of EBV latent 
proteins can be detected (Table 1.1: latency III program) [77, 78].  
  
Even with the comprehensive classification of PTLD published by the 
World Health Organization in 2008 (Table 1.2), the diagnosis of PTLD 
can still be complicated with misdiagnosis of infection or graft rejection 
[79]. Furthermore, the design of a controlled randomized study with 
proper controls to compare the efficacy of current drugs in PTLD 
treatment is inherently difficult owing to the diverse range of organs 
transplanted, disease spectrum and age-related manifestations of the 
disease. Therefore, it is to no surprise that the small sample sizes of 
published trials from individual centers can be conflicting at times. 
Taken together, it is evident that there are still a number of hurdles to 
surmount in the treatment of PTLD.   
 
 




1.3.1 Host immunity in PTLD  
 
The earliest indication of T cell immunity targeting EBV-infected B cells 
came from Rickinson et al., where donor-derived T cells were able to 
inhibit EBV-induced transformation in vitro  [80-82]. Following the 
introduction of pMHC tetramer staining for EBV-specific CD8+ CTLs, 
Callan et al. were the first to characterize EBV-specific T cell immunity 
and reported 44% of the CD8+ T cells from the peripheral blood of an 
individual to be specific for the virus [83].  
 
The responsiveness of T cell immunity to the virus was further 
highlighted by the massive expansion of EBV-specific T cells during 
primary EBV infection and the establishment of a T cell memory 
repertoire upon resolution of acute infection [84, 85]. The importance of 
T cell immunity in EBV-PTLD is well-illustrated in transplant recipients, 
where anti-thymocyte globulin conditioning regimen to prevent graft 
rejection confers an increased risk of PTLD development [86]. 
Consistently, in a longitudinal study of bone marrow transplant patients, 
the reduction of immunosuppression resulted in the recovery and 





Humoral immunity, on the other hand, is crucial in preventing the 
spread of EBV via neutralization of the virus [89]. While the role of 
humoral immunity in PTLD is less clear, it is established that transplant 
recipients with EBV-specific humoral immunity prior to transplantation 
are protected from PTLD development [90, 91]. Indeed, Riddler et al. 
demonstrated that transplant recipients with deficient humoral 
responses against EBNA-proteins were predisposed to PTLD 
development, with disease development inversely correlating to the 









1.4 Treatment of PTLD overview 
 
Various treatment modalities are available for PTLD (Table 1.3). Yet, 
opinions differ on their utility due to the lack of comprehensive clinical 
trials to assess and compare the relative treatment efficacy of different 
therapeutics. In this section, the most commonly employed approaches 
to managing PTLD, namely the RIS, anti-B cell monoclonal antibody 
(rituximab), and T cell adoptive therapy are discussed (Table 1.3). The 








1.4.1 Reduction of immunosuppression (RIS) 
 
Unlike other treatment approaches that involve the administration of 
therapeutics into transplant recipients, RIS is considered as PTLD 
management rather than treatment. RIS is achieved by decreasing the 
dosage of immunosuppressants to facilitate the recovery of host 
immunity against the EBV-infected B cells. Although RIS is the clinical 
mainstay in PTLD management, its practice can increase the risk of 
graft rejection. Thus, careful considerations have to be made in the 
case of heart transplant recipients, where organ replacement or 





1.4.2 Anti-B cell monoclonal antibody  
 
Rituximab is a therapeutic monoclonal antibody which binds and 
depletes CD20-expressing cells. The antibody is currently the best-
selling oncology drug [94],  and is used in the treatment of lymphoma 
[95], leukemia [96], rheumatoid arthritis [97] and lupus [98]. In the 
context of PTLD treatment, a number of groups expressed concern on 
the clinical employment of rituximab as the antibody’s non-selective 
elimination of healthy B cells can have a dampening effect on humoral 
immunity, which is required for long-term protection against EBV [99]. 
In addition, the use of rituximab has been reported to increase the risk 
of opportunistic infections [100, 101], and the development of refractory 
CD20‒ lymphoma [102, 103]. Nonetheless, the therapeutic efficacy of 
rituximab under different transplantation settings has been 
demonstrated, either in the form of a single-agent or as a combinatory 
treatment with other drugs [104-110]. Evidently, the use of rituximab 
supports the feasibility of employing antibodies for PTLD treatment, 
while at the same time highlighting a need for therapeutics with better 




1.4.3 Adoptive T cell therapy  
 
Adoptive T cell therapy involves the infusion of viral- or tumor-specific T 
cells into a patient to eradicate the diseased cells. The usage of EBV-
specific T cells for adoptive T cell therapy came from the early 
observation by Rickinson et al., that T cells from EBV-seropositive 
donors could inhibit EBV infection in vitro [80]. In the 1990s, the first 
two human trials using adoptive T cell therapy were acclaimed for their 
successes in the treatment and prevention of PTLD in solid organ 
transplant and bone marrow transplant recipients [111-113].  
 
Of note was the landmark human clinical trial conducted by Rooney et 
al., where 39 patients prophylactically infused with donor-derived EBV-
specific T cells demonstrated protection against lymphoma 
development, while 7/61 patients in the control group developed the 
disease [112]. The same study also validated the safety aspects of 
EBV-specific T cell therapy, their potency as immunoprophylaxis and 
their feasibility in the treatment of established PTLD. Subsequently, 
many other human trials reported successes with EBV-specific T cell 
therapy, attesting to the employment of this approach in PTLD 




In spite of the success with EBV-specific T cell therapy, it is not a 
readily available treatment option because the isolation and expansion 
of EBV-specific T cells from donors is a complex process that can span 
up to 12 weeks [121]. As this treatment modality requires human 
leukocyte antigen (HLA)-matching, the limited banking plus the time-
consuming procedures in generating compatible EBV-specific T cell 
lines restrict its clinical utility. To overcome these limitations in 
producing EBV-specific T cells, Icheva et al. developed a rapid protocol 
for generating EBNA-1-specific T cell lines within 72 hours [122]. 
Notably, the authors reported that EBNA-1-specific T cells obtained 
from this rapid protocol could confer protective T cell immunity, 
preventing the development of PTLD. This study not only provides a 
methodology to enhance the production of EBV-specific T cells but also 
supports the feasibility of targeting EBNA-1 in PTLD treatment.  
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1.4.4 TCR-like mAbs  
 
TCR-like mAbs are antibodies which exquisitely recognize a specific 
pMHC (Figure 1.4). The increasing interest in TCR-like mAbs is 
evident by the growing repertoire of TCR-like mAbs extending into 
areas of research, diagnostics, and therapies of cancers [123-125] and 
infectious diseases [126-128]. TCR-like mAbs are endowed with the 
specificity of a T cell receptor and have been employed for antigen 
presentation studies [127-131]. As shown in Figure 1.5, these 
antibodies have been reported to mediate the direct induction of 
apoptosis, complement-dependent cytotoxicity (CDC), and antibody-
dependent cell-mediated cytotoxicity (ADCC) [123, 125, 132-135].  
  
As a protein derivative, TCR-like mAbs have some advantages over 
effector T cells, in that they may be less susceptible to 
immunomodulatory cytokines in the tumor microenvironment which 
suppress anti-tumor functions [132]. More importantly, antibodies are 
stable and can be purified in large quantities for in vivo applications 
[136]. As the development of TCR-like mAbs is a relatively new 
phenomenon, efforts have been focused on establishing the 
groundwork for future application of these antibodies in the clinic [137, 
138]. In the context of PTLD, our laboratory has previously suggested 
the potential utility of EBV-specific TCR-like mAbs for the treatment of 
EBV-associated diseases [129].  
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In this study, three EBV-specific TCR-like mAbs were utilized to 
delineate the antigen presentation hierarchy of EBV latent proteins 
EBNA-1562-570, LMP1125-133 and LMP2A426-434 on HLA-A*0201 cells. 
Apart from the high binding affinities reported, these EBV-specific TCR-
like mAbs were reported to be able to detect the endogenous 
presentation of these latent proteins in EBV-infected cell lines, with 
EBNA-1 epitope being the most abundantly presented. Importantly, this 
study has provided insights on the targeting of intracellular antigens 
which are often ‘hidden’, but made accessible upon surface 
presentation. As these antibodies were only used for the purpose of 
studying MHC class I antigen presentation, we proposed that it would 





Figure 1.4: Schematic of pMHC binding to T cell receptor and TCR-
like mAb. Left: T cell receptor is found on the surface of T cells, 
recognizing antigen/peptide presented on the MHC class I molecules. 
The destruction of tumor or virus-infected cells is based on TCR 
recognition. Right: TCR-like mAb is an antibody with specificity akin to 
that of a TCR, recognizing the surface presentation of pMHC.    
 






















































































































































































































































































1.5 In vivo models overview 
 
Murine models play an important role in biomedical research and their 
usage has accelerated our understanding of numerous diseases. With 
regards to disease modeling and therapeutic testing, in vivo models are 
preferred over the use of cell lines as cells are often over-simplified in 
that they lack the physiological complexity of an organ system.  
 
EBV as a gammaherpesvirus infects only humans and higher primates, 
and this consequently complicates the development of mouse models 
of EBV infection. While primates such as marmosets, cotton-top 
tamarins, and owl monkeys can be infected with the virus, they are 
either endangered or costly to maintain. Thus, there are limited animal 
model available for the establishment of EBV infection in vivo. To 
overcome the limitation of modeling EBV-associated disease in mice, 
Mosier et al. pioneered the injection of PBL from EBV-seropositive 
donors into severe combined immunodeficient (SCID) mice to simulate 
EBV-positive B cell lymphoma [139]. The methodology employed by 
Mosier et al. not only simulated the development of EBV-PTLD in bone 
marrow transplant recipients but also established the first mouse model 
reconstituted with a human hematolymphoid system.  
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The establishment of a mouse model with the human immune system 
by Mosier et al. opened up a new era of mouse modeling, now referred 
to as the humanized mice. With the advancements in genetic 
engineering and animal breeding, NOD/SCID/IL2Rγ‒/‒ (NSG) mice 
were generated to better support human immune cells engraftment 
[140]. As these mice are highly immunodeficient, they are able to 
support the engraftment of human hematopoietic progenitor cells 
(HPCs), giving rise to the de novo generation of human B cells that are 
permissive to EBV infection in vivo.  
 
The advent of humanized mice is in-line with the demand for an animal 
model which is relevant for modeling human diseases and possesses a 
high predictive value for therapeutics evaluation. The necessity of an 
animal model which can faithfully predict human responses to drug 
treatment is illustrated by one of the most catastrophic human trial of 
anti-CD28 antibody (TGN1412). In that particular clinical trial, all six 
healthy volunteers developed cytokine storm followed by multiorgan 
failure despite being administered with TGN1412 at a dosage which 





Owing to the species-specific, immunopharmacological differences 
between humans and animals, these tested animals failed to predict 
the development of a cytokine storm as the result of T cell activation in 
humans upon TGN1412 treatment [141]. This incident clearly 
exemplifies that the interaction between any therapeutic candidate in 
question and the human immune system should be thoroughly 
evaluated, and further highlights a need for a more robust animal 
model. In this regard, the humanized mice provide not only human 
immune cells for disease modeling; they are also amenable for 
predicting human immune responses to potential immunotherapeutics. 
Indeed, a recent publication by Weissmuller et al. demonstrated that 
the humanized mice are able to recapitulate the adverse effects as 




1.5.1 Mouse xenograft model 
 
Xenograft modeling involves the transplantation of human tumor 
tissues or cells into immunodeficient mice. As these mice are devoid of 
a functional mouse immune system, human tissues/cells can be 
engrafted with minimal rejection. In the first mouse model of EBV-
associated disease, Mosier et al. injected PBL from EBV-seropositive 
donors into immunodeficient C.B-17-SCID mice to simulate the 
development of EBV-positive B cell lymphoma in immunocompromised 
bone marrow transplant recipients [139]. When 5 X 107 PBL was 
injected into the immunodeficient C.B-17-SCID mice, B cell tumors 
were observed with histology similar to the lymphomas in EBV-PTLD 
patients [139, 145]. In contrast, no tumors were observed when 1 X 107 
PBL was used.          
 
The lack of B cell lymphoma development in mice injected with 1 X 107 
PBL can be attributed to the low frequency of EBV-infected cells in the 
peripheral blood [146, 147]. However, it should be noted that although 
C.B-17-SCID mice are deficient in functional B and T cells, they have 
an intact innate immunity and that could impede the engraftment of 
EBV-infected B cells [148]. Due to the suboptimal reconstitution 
conditions provided by the C.B-17-SCID mice, as well as the low 
numbers and variability of EBV-infected B cells in the peripheral blood 
between donors, modeling EBV-PTLD with reproducibility and 
consistency is challenging.   
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To overcome the reproducibility issue, Rowe et al. injected BLCL as an 
alternative to PBL from EBV-seropositive donors to model EBV-PTLD 
(Figure 1.6) [149, 150]. The use of BLCL as a replacement of PBL was 
justified as the surface phenotype, karyotype, and viral gene 
expression of BLCL are analogous to the tumors in PBL-SCID mice. 
Using this approach, graft-versus-host disease as seen with the 
transfer of mature human T cells present in the PBL could be 
circumvented [151]. At the same time, this also ensured a more reliable 
development of B cell tumors in the mice. Consequently, the 
methodology of injecting BLCL into SCID mice became a basic model 
of EBV-PTLD and has since been used for the assessment of 
treatments such as adoptive T cell therapy [152-156].   
 
As illustrated by the TGN1412 human trial, differences in the 
immunopharmacological characteristics between species could 
possibly be the reason why humans reacted differently from tested 
animals. In this regard, the lack of a human immune system in the 
mouse xenograft model of EBV-PTLD does not allow the assessment 
and prediction of human immune responses to therapeutics. As such, 
there is the need for an animal model that can recapitulate key features 
of EBV-PTLD and enable the examination of individualized human 
immune responses to treatments in order to provide a more accurate 
























































































































































































































































































































































































































































































































































































































































1.6 Humanized mouse model overview 
 
Humanized mice or more specifically human hematolymphoid system 
mice are commonly defined as immunodeficient mice which are 
engrafted with human immune cells (Figure 1.7). The generation of a 
humanized mouse is laborious due to the requirements of specialized 
housing and technical expertise in the delivering of CD34+ HPCs during 
the reconstitution process. Two main factors can determine the 
success of generating a humanized mouse: the sources and quality of 
the human sample, as well as the strain of recipient mouse.   
 
Human PBL, cord blood, and fetal liver are common sources of human 
cells used for the generation of humanized mice. The use of donor-
derived cells in the humanized mice enables the construction of a 
mouse model which can reflect donor-specific disease heterogeneity 
and individualized responses to the tested therapeutics. In the first 
humanized mouse model, graft-versus-host disease was reported due 
to the presence of mature T cells in PBL that attacked the mouse 
tissues [139, 151]. However, such complication is avoided with the use 
of HPCs from the fetal liver [157] and cord blood [158]. Unlike 
circulating T cells which are committed to non-self recognition, HPCs 
are the blood precursor cells and thus do not mediate graft-versus-host 
disease. By far, de novo hematopoiesis of B cells, T cells, NK cells, 
monocytes, macrophages and dendritic cells have been observed after 




The choice of mouse strain is a key determinant in human immune 
cells reconstitution. Initially, the C.B-17-SCID mouse was used for the 
reconstitution of human immune cells but this system supported the 
engraftment poorly due to the presence of mouse innate immunity 
(Table 1.4) [139]. To improve the reconstitution of human immune cells 
in mice, Hesselton et al. generated the NOD-SCID mice which have 
reduced NK cell activity [159]. While the NOD-SCID mice was shown to 
better support human immune cells engraftment as compared to the 
C.B-17-SCID strain, they have shortened life span due to thymic 
lymphoma development, limiting their usage for long-term studies [160].  
 
In 2002, Ito et al. crossed the NOD-SCID mouse with a mouse 
harboring a null mutation for interleukin-2 receptor subunit gamma 
(IL2Rᵧ) to giving rise to the NOD/SCID/γcnull mice which are defective in 
NK cell activity [161]. As IL2Rᵧ is a common cytokine receptor subunit 
required for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, the 
absence of IL2Rᵧ in NOD/SCID/γcnull mice resulted in the blockage of 
NK cell development [161-163]. Further characterization by Shultz et al. 
revealed that these mice have severe defects in both their innate and 
adaptive immunity. However, unlike their parental NOD-SCID strain, 
NOD/SCID/γcnull mice do not develop thymic lymphoma and are better 
in supporting the engraftment of human immune cells [140]. At present, 
this strain of mouse is known as the NSG mouse and is one of the 




With the increasing demands for a humanized mouse model, newer 
strains of mice such as the BALB/c-Rag2‒/‒IL2Rγ‒/‒ mouse have been 
generated to enhance the maturation of reconstituted human B cells 
[164]; and the transgenic expression of human signal regulatory protein 
alpha in the Tg(hSIRPα)Rag2‒/‒IL2Rγ‒/‒ mouse strain improves the 
tolerance of murine macrophages towards engrafted human immune 
cells [165]. To date, the humanized mouse model has been employed 
to study a number of human pathogens with tropism for human 
immune cells such as EBV [164], Salmonella typhi [166], human 
cytomegalovirus [167], dengue virus [168], human immunodeficiency 
virus [169], Kaposi’s sarcoma-associated herpesvirus [170], hepatitis B 








1.6.1 Humanized mouse model of EBV-associated diseases 
 
The engraftment of HPCs and their subsequent differentiation into B 
cells in the immunodeficient mice enables the establishment of an in 
vivo EBV infection model. Since the first described HPCs-engrafted 
humanized mouse model of EBV infection developed by Traggiai et al. 
in 2004 [164], the humanized mice platform has been used for the 
modeling of EBV-associated diseases such as lymphoproliferative 
disorder [173, 174], hemophagocytic lymphohistiocytosis [175], HL 
[176], diffuse large B cell lymphoma [177, 178] and rheumatoid arthritis 
[179]. The modeling of asymptomatic infection reminiscent of latent 
EBV infection in humans has also been reported in the humanized 
mice when the virus is inoculated at <101 50% transforming dose [173]. 
 
B cell lymphoproliferative disorder and B cell lymphomas are the most 
commonly studied EBV-associated diseases in humanized mice. In the 
first humanized mouse model of EBV lymphoproliferative disorder, 
Yajima et al. were able to recapitulate salient features of EBV-PTLD in 
humans such as the detection of EBV viral DNA and the manifestation 
of lymphoproliferation in the spleens, livers and kidneys [173]. In 
addition, the observed disease phenotype, histology and the 
expression of latency III profile in the humanized mice were consistent 
with the disease presented in immunocompromised humans. 
Intriguingly, EBV-specific T cells and IgM antibody responses were 
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detected despite the development of both human B and T cells in the 
microenvironment of their murine recipients.  
 
Based on the establishment of B cell lymphoproliferative disorder by 
Yajima et al., many research groups have since utilized this platform to 
study disease pathogenesis, immune responses and therapeutic 
approaches in the context of EBV-PTLD (Table 1.5). In particular, Ma 
et al. investigated the role of lytic cycle activator (BZLF1) in the 
humanized mice and demonstrated that BZLF1-defective EBV has an 
impaired ability in tumor formation in vivo [177]. Through this model, 
researchers have further uncovered an unexpected tumor suppressor 
role of EBNA-3B, in facilitating T cell-mediated killing of EBV-infected B 
cells [178]. Such a finding is intriguing, as the tumor suppressor role of 
EBNA-3B is incongruous to the oncogenic potential of EBV.  
 
The use of humanized mice has also revealed the multifaceted roles of 
T cells in the pathogenesis of the EBV-associated lymphoproliferative 
disorder. The involvement of T cells in determining disease progression 
and pathogenesis was illustrated by Lee et al., where the disease 
outcome was dependent on the proportion of T cells in the humanized 
mice [176]. The importance of T cell immunity was also demonstrated 
in the humanized mice and exploited as a treatment modality, with the 
adoptive transfer of EBV-specific T cells reducing EBV viremia [180]  
and prolonging the lifespan [181] of treated mice. On the other hand, 
an alternate aspect of T cell functionality was observed with CD4+ T 
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cells, where they were shown to downregulate the immunogenicity of 
EBV-infected B cells, diminishing their recognition by CD8+ T cells 
[182].  
 
In a recent report by Ma et al., human T cells within humanized mice 
were found to be inhibited by the expression of programmed cell death-
ligand 1 on EBV-infected cells [183]. The inhibition of T cells could 
however be reversed upon the treatment with anti-PD-1 monoclonal 
antibody which has been approved by the FDA for the treatment of 
melanoma and squamous non-small cell lung cancer [184]. Despite the 
discrepancies in the reported T cell functions from different studies, 
these studies converge on the importance of T cells in shaping the 
outcome of the disease. Taken together, the humanized mouse model 
of EBV infection not only contributes to the understanding of disease 

















































































1.6.2 Improvements on the humanized mouse model 
 
Since the introduction of humanized mouse technology 30 years ago, 
various efforts have focused on improving the specificity of T cells and 
engraftment of human innate cells in the humanized mice. The lack of 
specificity in the reconstituted T cells could be attributed to the 
suboptimal development and maturation processes involving the 
interactions between human T cells and pMHC on murine thymic 
epithelial cells [185]. To circumvent the lack of specificity, McCune et al. 
developed the BLT (bone marrow-liver-thymus) humanized mouse, 
which requires the co-implantation of fetal liver and fetal thymus, 
followed by the injection of autologous HPCs [157, 186].  
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The BLT mice are regarded as the gold standard of humanized mouse 
models as they provide a more extensive engraftment of human 
immune cells, with human immune cells reconstitution observed in the 
reproductive and gastrointestinal tract of mice, catering to the study of 
the mucosal transmission of HIV [187, 188]. Furthermore, due to the 
implantation of human thymic organoid, reconstituted human T cells 
are positively selected in the human leukocyte antigen milieu, giving 
rise to specific immune responses. In the context of EBV, Melkus et al. 
demonstrated that the reconstituted human T cells in BLT humanized 
mice were capable of mounting HLA-restricted EBV-specific responses 
[174, 189].  In spite of the advantages of BLT humanized mice, the 
limited availability of fetal samples and the requirement of surgical 
procedures restrict its widespread adoption and usage in laboratories.  
 
The improvement of human innate cells reconstitution is another 
aspect which has gained significant attention in recent years. Although 
the use of immunodeficient mice has improved the engraftment of 
human immune cells, due to the lack of appropriate cytokine for 
differentiation and maintenance, the reconstitution of human innate 
cells and NK cells have remained low [190-192]. To enhance the 
reconstitution of these cells, many approaches such as cytokine 
transgene expression [193-195] and the injection of cytokines [196, 




While these approaches are reliable in enhancing the reconstitution of 
human immune cells, each has their own disadvantages. The 
employment of cytokine transgene expression ensures constitutive 
gene expression. However, the development of transgenic mice is 
technically difficult and time-consuming. In the most sophisticated 
transgenic mice, Rongvaux et al. generated the MITRG (Human 
macrophage colony-stimulating factor, IL-3/granulocyte macrophage 
colony-stimulating factor and thrombopoietin transgenic 
Rag2‒/‒IL2Rγ‒/‒ mice) and MITSRG (MITRG mice with human SIRPα 
transgene) mice to enhance the development and function of human 
innate cells and NK cells [200]. Reportedly, the reconstituted human 
NK cells and phagocytes in these transgenic humanized mice were 
capable of eliciting cytotoxicity and phagocytosis respectively. While 
these mice are available commercially, they are costly to acquire. A 
similar consideration of cost is ascribed to the use of cytokine injection. 
Due to the short-lived effects of cytokines, multiple maintenance 




HDI of vectors encoding human cytokines is an alternative approach to 
improve the reconstitution of human immune cells. HDI is a technique 
introduced by Suda et al. in 2007, where a large volume of plasmids-
containing solution is rapidly injected into a mouse, causing high 
pressure to the liver, forcing the uptake and subsequent expression of 
these plasmids by hepatocytes [201]. Such method has been 
demonstrated to be efficient and cost-effective, with the systemic 
distribution of the expressed human cytokines enhancing the 
differentiation of reconstituted human immune cells [198, 202, 203].  
 
One major area that still requires more effort is the reconstitution of 
human epithelial cells for modeling oropharyngeal EBV infection in vivo. 
As the oropharyngeal site is an important niche for EBV infection, the 
lack of human epithelial cells restricts recapitulation of a complete EBV 
life cycle in the humanized mouse. Future endeavors on the 
humanized mouse modeling will have to strive towards the 
enhancement of human hematopoiesis and the development of more 
robust immune responses that bear a closer resemblance to that of 
humans. High cost, intensive technical skill and the need of 
controversial fetal samples are the challenges that have to be 















Chapter 2:  
Materials and Methods  
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2.1 Declarations  
 
Human umbilical cord blood was obtained from the Singapore Cord 
Blood Bank. Human fetal tissues (livers, femurs, and spleens) were 
obtained from aborted fetuses from KK Women and Children Hospital, 
Singapore. All human samples were obtained with written informed 
consent from donors and in accordance with the institutional ethical 
guidelines stipulated by the Institutional Review Board. Animal 
experiments were performed under the provision of National University 




2.2 Cell lines 
 
Human Embryonic Kidney (HEK) 293T (ATCC® CRL-3216), T2 
(ATCC© CRL-1992TM), and Raji (ATCC© CCL-86TM) cells were 
purchased from ATCC©. C1R-A2 (C1R BLCL transduced with HLA-
A*0201) cells were kind gift from Dr. Gan Shu Uin (National University 
of Singapore, Department of Surgery). BLCLs (Table 2.1) with 
determined HLA-A haplotype, BJAB, and B95-8 marmoset cell lines 
(B95-8 EBV) were kind gifts from Emeritus Professor Chan Soh Ha 
(WHO Immunology and Training Research Centre, Singapore). 
Primary macrophages were cultured in Dulbecco's Modified Eagle 
Medium (DMEM). Unless stated, all cells were cultured in Roswell Park 
 43 
 
Memorial Institute (RPMI)-1640 medium. Both DMEM (HycloneTM) and 
RPMI-1640 (Biowest) culture medium were supplemented with 10% 
(v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin 
(GibcoTM). All cells were cultured at 37oC in 5% CO2 incubator. For 
cryopreservation, cells were resuspended in 1 ml of freeze medium 
(90% FBS and 10% dimethyl sulfoxide v/v), transferred into a cryogenic 
vial and placed in a CoolCell® cell freezing container.  
 
 
       
Table 2.1: HLA-A haplotype of BLCLs 
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2.3 Peptides  
 
All peptides were synthesized by Mimotopes with purity (>95%) 






2.4 Peptide pulsing 
 
2 X 106 cells were treated with 1 ml of citric acid medium (pH 3.0 in 1% 
bovine serum albumin (BSA) w/v) for 2 min at 4oC to remove pre-
existing surface pMHC complexes prior to peptide pulsing. Cells were 
washed twice with 1X phosphate-buffered saline (PBS), pulsed with the 
respective peptides as shown in Table 2.2 and incubated for 3 h at 
37oC with 5% CO2 incubator. Pulsed cells were then washed and 
stained with α-EBNA TCR-like mAb (refer to section 2.17.1 for details 
on using α-EBNA TCR-like mAb for the staining of surface EBNA-1 
pMHC).  





Unconjugated antibodies included both commercial and in-house 
produced α-EBV TCR-like mAbs (Table 2.3). Conjugated secondary 
antibodies, Alexa Flour® 488 goat α-mouse IgG (H+L) antibody (#A-
11001), Alexa Fluor® 488 goat α-rat IgG (H+L) antibody (#A-11006), 
goat α-mouse IgG horseradish peroxidase (HRP) (#31430), and goat 
α-rabbit IgG HRP (#31460) were purchased from Thermo Fisher 
Scientific. Fluorophore-conjugated antibodies for flow cytometry 
application were purchased from BioLegend and BD Biosciences 
(Table 2.4).  
 
HLA-A*02-restricted α-EBNA-1 TCR-like mAb was generated using the 
classical hybridoma technology and previously described in Ms. Eio 
Yating Michelle Master’s Thesis (ScholarBank@NUS #4087). For flow 
cytometry application, purified antibodies were diluted with glycerol, 
aliquoted at 1 mg/ml and stored at -80oC. Antibodies for phagocytosis 
assay and in vivo treatment were diluted in 1X PBS and sterile-filtered 






2.6 Site-directed mutagenesis  
 
α-EBNA-1 TCR-like mAb (FcγR-null binding variant) with D265A point 
mutation was generated by replacing aspartic acid at position 265 with 
alanine using the QuikChange Site-Directed Mutagenesis Kit 





Table 2.3: List of unconjugated antibodies 
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Fluorophores: allophycocyanin (APC), cyanine 5.5 (Cy5.5), cyanine 7 
(Cy7), fluorescein isothiocyanate (FITC), phycoerythrin (PE), and 









2.7 Plasmids construction 
 
Both wild type (WT) EBNA-1 (1923 nucleotides) and E1∆GA (1218 
nucleotides) were cloned into pUC57 (GenScript). DNA fragments 
incorporating BamHI and XbaI restriction sites were amplified with 
AccuPrime™ Pfx DNA polymerase (Invitrogen) using sense primer 
sequence (5’-TTGGATCCACCATGTCTGACGAGGGGCCAGGTACA-
3’) and antisense primer sequence (5’-
TTTCTAGACCCTCCTGCCCTTCCTCACCCTCATC-3’). Polymerase 
chain reaction (PCR) was performed in accordance to manufacturer’s 
protocol (Invitrogen). PCR amplicons were then subjected to 1% gel 
electrophoresis, gel extracted with QIAquick® gel extraction kit (Qiagen) 
and cloned into the BamHI and XbaI restriction sites of pcDNA™3.1 
V5-His-TOPO vector (Invitrogen). For the incorporation of green 
fluorescent protein (GFP)-2A into the 5’ upstream of WT EBNA-1 and 
E1∆GA (both constructs were in pcDNA™3.1 V5-His-TOPO vector as 
described above), DNA fragments incorporating flanking BamHI 
restriction sites were amplified with AccuPrime™ Pfx DNA polymerase 
using sense primer sequence (5’-GGATCCATGGTGAGCAAGGGC-3’) 
and antisense primer sequence (5’- GGATCCGGGCCCAGGGTT-3’). 
All constructs were transformed into JM109 competent cells (Promega) 
and plated on ampicillin plate for selection. Sanger sequencing (1st 
BASE) was performed to verify clones prior to large-scale plasmid 




2.8 Plasmid transfection 
 
HEK293T cells were seeded at a density of 1 X 105 cells per well (in a 
6-well plate) in penicillin-streptomycin-free culture medium on the day 
before transfection. Transfection was performed using plasmids 
encoding WT EBNA-1, E1∆GA, GFP-2A WT EBNA-1, and GFP-2A 
E1∆GA. 4 µg of each endotoxin-free plasmid was transfected into cells 
using Lipofectamine® 2000 Transfection Reagent (Invitrogen). 
Transfection was performed according to manufacturer’s protocol. 
Cells were harvested at various time points for Western blot and flow 
cytometric analysis.  
 
 
2.9 Western blot analysis 
 
Cells were pelleted and lyzed with 1X radioimmunoprecipitation assay 
(RIPA) buffer (Millipore) containing ethylenediaminetetraacetic acid 
(EDTA)-free protease inhibitor (Roche) for 15 min on ice. Bradford 
protein quantification assay was performed and 40 µg of cell lysates 
were boiled (with SDS and β-mercaptoethanol) at 95oC for 10 min. 
Samples were separated on 10% SDS-PAGE and transferred onto a 
polyvinylidene difluoride membrane. Membranes were blocked 
overnight at 4oC with 5% (w/v) skimmed milk (Sigma-Aldrich) diluted in 
1X PBST (0.1% Tween-20 in 1X PBS). Both primary and secondary 
antibodies were diluted with 3% (w/v) skimmed milk. Protein detection 
 51 
 
was performed using Western Lightning Chemiluminescence (Perkin 
Elmer) and exposed onto a photographic film (GE Healthcare).  
 
2.10 pMHC enzyme-linked immunosorbent assay (ELISA) 
 
Biotinylated recombinant human HLA-A*0201 molecules (5 µM) with 
bounded UV-cleavable peptides were subjected to UV light for 15 min 
on ice to initiate peptide exchange. 500 µM of rescue peptides (EBNA-
1 peptide, FMVFLQTHI) or control peptides from influenza A virus 
M158-66 were added and incubated at 37
oC for 1 h to facilitate the 
exchange. pMHC complexes with their respective exchanged peptides 
were added onto streptavidin-coated ELISA plate in quadruplicates and 
incubated for 1 h on ice to allow binding to the coated streptavidin. The 
plate was washed four times with 1X PBST prior to the addition of the 
10X serially diluted α-EBNA-1 TCR-like mAb. The plate was incubated 
on ice for 90 min and washed four times with 1X PBST before adding 
25 µl of HRP-conjugated goat α-mouse antibody (diluted in 1:10,000 
with 2% BSA in 1X PBS). The reaction was incubated for another 30 
min on ice and washed before adding 25 µl of 2, 2’-azino-bis (3-
ethylbenzothiazoline-6-sulphonic acid) substrate solution (Invitrogen). 
The plate was incubated at room temperature (RT) for 15 to 20 min to 
allow the reactions to develop. 12.5 µl of stop buffer containing 1% 
sodium azide and 0.1 M citric acid was added to halt further 
colorimetric changes. Absorbance was measured on a 
spectrophotometer at 415 nm. 
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2.11 EBV production 
 
The B95-8 marmoset cell line producing a prototypic B95-8 strain of 
EBV was cultured for virus production. Cells were seeded at a density 
of 1 X 106 cells/ml, and induced with 0.3 M of sodium butyrate and 200 
ng/ml of 12-O-Tetradecanoylphorbol-13-acetate for 48 h. Thereafter, 
cells were washed with culture medium to remove inducer, re-seeded 
at a density of 1 X 106 cells/ml and further cultured another 14 days 
without passaging. After 14 days of starvation, the culture supernatant 
was then centrifuged and filtrated through a 0.45 µm syringe filter. 
Aliquots of 15 ml virus supernatant were stored at -80oC.  
 
 
2.12 BLCL generation  
 
For in vitro EBV infection, cells were resuspended to a density of 2 X 
106 cells/ml, with an equal volume of EBV supernatant added. The cell-
virus mixture was then incubated at 37oC with 5% CO2 incubator for 2 h.  
After incubation, cells were washed, pelleted and resuspended to a 
density of 1 X 106 cells/ml using culture medium supplemented with 1 
µg/ml cyclosporin A (Sigma-Aldrich). Cells were then aliquoted at 100 
µl per well in a 48-well plate, and incubated for two to three weeks for 
the formation of macroscopic B cell clusters. Culture medium was 




2.13 Annexin V apoptosis assay 
 
1.0 X 105 BLCL was resuspended in Opti-MEM® Reduced-Serum 
Medium (GibcoTM) and seeded onto a 24-well plate. Cells were treated 
with 1 µg (or 10 µg) of α-EBNA-1 TCR-like mAb and incubated at 37oC 
with 5% CO2 incubator. As a positive control, cells were treated with 1 
µM camptothecin (anti-neoplastic alkaloid) to induce apoptosis. Mouse 
IgG1 isotype control antibody treatment was used as a negative control.  
Cells were harvested at 6 h and 24 h time points, pelleted and washed 
with 1 ml of 1X annexin binding buffer. A master mix constituting of 1 µl 
of 7-Aminoactinomycin D (7-AAD) (Sigma-Aldrich) and 2 µl annexin V 
Pacific BlueTM Conjugate (Thermo Fisher Scientific) per sample was 
prepared and added to each tube. Incubation was carried out at RT (in 
the dark) for 15 min. 200 µl of 1X annexin binding buffer was added to 
each sample prior to flow cytometry acquisition.  
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2.14 Cell isolation techniques  
 
2.14.1 PBMC (peripheral blood mononuclear cells) isolation 
 
Human peripheral blood was collected using BD Vacutainer® K2 EDTA 
(K2E) blood collection tube (BD Biosciences). The collected blood was 
mixed well with 1X sterile-filtered PBS (in 1:1 ratio). 30 ml of the blood 
mixture was then layered over 15 ml of Ficoll-Paque PLUS (GE 
Healthcare Life Sciences) in a 50 ml conical centrifuge tube (in the ratio 
of 2 ml of blood mixture: 1ml of ficoll). Cells were centrifuged at 400 X g 
for 30 min at RT (brake OFF). After centrifugation, PBMC was 
aspirated from the Ficoll-plasma interface using a 2 ml Pasteur pipette. 
Cells were then washed twice with 30 ml of 1X PBS and centrifuged at 
300 X g for 5 min. Isolated PBMC was either utilized for the generation 
of BLCL or processed for the staining with α-EBNA-1 TCR-like mAb.  
 
 
2.14.2 HPCs isolation 
 
HPCs were isolated using EasySepTM Human CD34 Positive Selection 
Kit (STEMCELL Technologies), in accordance with the manufacturer’s 
protocol. An equal volume of 0.2 mM EDTA 1X PBS was added to the 
cord blood, mixed and gently layered onto Leucosep® Tubes (Greiner 
Bio-One) containing 15 ml of Ficoll-Paque PLUS. Blood fractionation to 
separate the buffy coat from the plasma and erythrocyte fractions was 
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conducted as per PBMC isolation. Several fractions of the buffy coat 
were pooled, pelleted and resuspended in 10 ml of ACK (ammonium-
chloride-potassium) lysis buffer (GibcoTM). Red blood cells were lyzed 
for 10 min at RT. 40 ml (4X volume of lysis buffer) of 0.2 mM EDTA 1X 
PBS was added to quench the lysis reaction prior to immunomagnetic 
cell separation. Automated cell separation was performed with a pre-
programmed and customized CD34+ selection protocol on the 
RoboSep™ machine. Cells were isolated under sterile condition, and 




2.14.3 Human CD19 positive cells isolation  
 
Immunomagnetic selection of human CD19 positive cells was 
performed using EasySepTM Human CD19 Positive Selection Kit 
(STEMCELL Technologies), in accordance with the manufacturer’s 
protocol. A single cell suspension of fetal liver CD34‒ fraction, fetal 
bone marrow, and fetal spleen were resuspended to the density of 2.5 
X 106 cells/ml. Positive selection cocktail which contained a 
monoclonal antibody specific for CD19 was added to the cells and 
incubated at RT for 15 min. EasySep® Magnetic Nanoparticles were 
added to the cells, mixed and incubated at RT for 10 min. The mixture 
was inserted into a magnetic holder, followed by decanting the 
supernatant in a single continuous motion. The tube was then returned 
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to an upright position with CD19 positive cells magnetically attached to 
the tube. Cells were washed thrice with 3 ml of 1X PBS. Isolated cells 




2.14.4 Murine macrophage isolation 
 
To obtain macrophage progenitor cells, femurs of BALB/c mouse were 
harvested with both ends of the epiphysis partially cut to enable 
flushing of the bone marrow. Flushing of the bone marrow was 
performed using a 27-gauge needle. Single cell suspension was 
obtained by homogenizing the bone marrow and passing the sample 
through a 70 µm cell strainer (Corning®). ACK lysing buffer was used 
for the removal of red blood cell. Cells were washed twice with 1X PBS 
and cultured in DMEM supplemented with 10% FBS (v/v), 1% (v/v) 
penicillin-streptomycin and 20 ng/ml of recombinant murine 
macrophage colony-stimulating factor (R&D Systems). Macrophage 
progenitor cells were cultured for seven days to allow macrophage 
differentiation. Differentiated macrophages were harvested for 




2.15 In vitro phagocytosis assay  
 
Murine bone marrow-derived macrophages were harvested from the 
femurs for phagocytosis assay. To determine the effect of α-EBNA-1 
TCR-like mAb pre-incubation on phagocytosis, 10 µg of α-EBNA-1 
TCR-like mAb was added to the BLCL and incubated for 24 h prior to 
phagocytosis. For phagocytosis assay, 0.5-1 X 106 macrophages were 
either seeded directly into a 12-well plate (for flow cytometry) or onto 
18 mm coverslip within a 12-well plate (for microscopy). Macrophages 
were cultured in DMEM supplemented with 10% FBS (v/v) and 1% (v/v) 
penicillin-streptomycin and allowed to adhere overnight for at least 20 h. 
On the day of phagocytosis, the culture medium of the macrophages 
was removed and replaced with Opti-MEM® Reduced-Serum Medium. 
In parallel, 0.25 µl of carboxyfluorescein succinimidyl ester (CFSE) was 
added to 4 X 106 BLCL and incubated at RT (in the dark) for 10 min to 
label the BLCL. 5 µg of α-EBNA-1 TCR-like mAb (or mouse IgG1 
isotype control antibody) was added to the labeled-BLCL and 
incubated for 3 h before co-culturing with the macrophages at the ratio 
of 1: 1 (macrophage: BLCL). Cells were co-cultured in a 37oC with 5% 
CO2 incubator for 4 h to allow phagocytosis to occur. Refer to section 
2.17.3 and 2.19.1 for flow cytometry and fluorescent microscopy 





2.16 In vivo experiments  
 
2.16.1 Mouse xenograft modeling and treatment regimen 
 
2 X 106 BLCL was injected into 15 weeks old NSG mouse via the tail 
vein. Mice were then euthanized one week post-injection, with bone 
marrows, blood, brains, kidneys, livers, lungs, and spleens harvested 
to check for the infiltration of BLCL. In another separate batch, mice 
were kept for disease monitoring and euthanized when mice had more 
than 20% weight loss or found moribund. Flow cytometry staining for 
human pan-leukocyte marker CD45 (hCD45), mouse pan-leukocyte 
marker CD45 (mCD45), and human CD19 was conducted to determine 
the percentage of BLCL infiltration. 
 
To evaluate the therapeutic effect of α-EBNA-1 TCR-like mAb, BLCL-
injected mice were treated with a single weekly injection of 300 µg of α-
EBNA-1 TCR-like mAb one week post-BLCL injection (on week 16). 
Mice treated with 300 µg of mouse IgG1 isotype control antibody 
(BioLegend) were used as a control. Criteria for euthanasia and flow 




2.16.2 Autologous humanized mice  
 
In-house bred NSG pups born within 48 h were sublethally irradiated 
with 100 cGy gamma irradiation. Frozen human cord blood CD34+ 
HPCs were thawed and counted by trypan blue exclusion. 2 X 105 
CD34+ HPCs were injected into each of the NSG pups via the 
intracardiac route. At 12 weeks post-reconstitution, facial bleeding 
followed by flow cytometry staining with mCD45 versus hCD45 were 
used to determine the percentage chimerism.  
 
To establish an autologous humanized mouse model, autologous 
BLCL was injected into humanized mice reconstituted with CD34+ 
HPCs from the same donor. 8 X 106 autologous BLCL was injected 
intravenously via the tail vein into matching humanized mice and 
monitored for 18 weeks (30 weeks old). Humanized mice injected with 
control medium were used as a control. Mice were monitored for their 
body weight and bled weekly for flow cytometric analysis of peripheral 




2.16.3 Hydrodynamic injection (HDI) 
 
pcDNA3.1 (+) vectors (Invitrogen) encoding human IL-15 and FMS-like 
tyrosine kinase 3 ligand (FLT3L) gene were purified separately using 
PureYield™ Plasmid Maxiprep Kit (Promega). A single intravenous 
injection of IL-15 and FLT3L plasmids (50 µg each) in 1.8 ml of 1X PBS 
was performed on 13 weeks old, fetal liver CD34+ HPCs-reconstituted 
humanized mice within 7 s using a 27-gauge needle. Mice were 
checked for their chimerism on week 12 and HDI was performed on 
week 13. Mice were injected with autologous BLCL generated from the 
fetal spleen at week 14 and bled weekly from week 14 to 17 for flow 





2.17 Flow cytometry acquisition and analysis 
 
Flow cytometry buffer solution contained 0.2% BSA (w/v) and 0.05% 
(v/v) sodium azide in 1X PBS. For live/dead staining, samples were 
resuspended with 300 µl of flow cytometry buffer before the acquisition.  
All samples were acquired on BD LSRFortessa™ (Becton Dickinson). 
Dead cells were excluded by DAPI (4', 6-diamidino-2-phenylindole) 




2.17.1 Surface staining (EBV pMHC) 
 
3 X 105 HLA-A*02 BLCL was harvested and resuspended in 100 µl of 
flow cytometry buffer. Cells were stained with 5 µl of 1 mg/ml α-EBV 
TCR-like mAb (α-EBNA-1 TCR-like mAb or α-LMP1 TCR-like mAb) and 
incubated for 3 h before staining with Alexa Flour® 488 goat α-mouse 
IgG (H+L) secondary antibody for 1 h. Non-HLA-A*02 BLCL and 
HEK293T cells were used as the control cell lines, while mouse IgG1 
isotype antibody was used as a staining control. The α-HLA-A2 
antibody was used as a positive control. nMFI was calculated by taking 






2.17.2 Surface staining (immunophenotyping)  
 
Immunophenotyping of BLCLs, human PBMC, human fetal tissues 
(livers, femurs, and spleens) and the peripheral blood of humanized 
mice was conducted. All primary cells (except BLCLs) were lyzed with 
ACK lysis buffer for 5 to 10 min at RT, washed and stained with a 
cocktail of different fluorophore-conjugated antibodies (Table 2.4). 
Staining was incubated at 4oC for 30 min, washed twice with flow 
cytometry buffer solution prior to acquisition.  
 
 
2.17.3 Surface staining (phagocytosis assay)  
 
Cells from phagocytosis assay (in a 12-well plate) were trypsinized, 
washed and stained with PE rat α-mouse CD11b. Staining was 
incubated for 30 min and washed twice prior to flow cytometry 
acquisition. Phagocytosis was defined by the CFSE+ CD11b+ cells in 
the second quadrant (Q2) of the CFSE (BLCL) versus CD11b 





2.17.4 Intracellular staining 
 
3 X 105 cells were permeabilized by resuspending in 250 µl of BD 
Cytofix/Cytoperm solution (BD Biosciences) and incubated at 4oC for 
20 min. Permeabilized cells were washed twice with 1 ml of BD 
Perm/Wash buffer, stained with 5 µl of 1 mg/ml commercial α-EBNA-1 
antibody and incubated at 4oC for 1 h. Staining with mouse IgG1 
isotype control antibody was used as a negative control. Subsequently, 
cells were washed and stained with Alexa Flour® 488 goat α-mouse 





2.18.1 Tissue processing and sectioning 
 
Fresh mouse organs were harvested and fixed in 10% neutral buffered 
formalin (Sigma-Aldrich) overnight. Fixed samples were then 
transferred to a semi-enclosed benchtop tissue processor (Leica 
Biosystems)  and processed on a preset protocol with programmed 
ethanol dehydration gradient of 50%, 70%, 80%, 90% and then twice in 
100%, for 1 h at each step. Subsequently, samples were incubated in 
xylene: ethanol (50%: 50%) followed by immersing twice in 100% 
xylene for 1 h before transferring to molten paraffin and embedded 
onto histology cassettes. Formalin-fixed paraffin-embedded samples 
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were stored at RT, sectioned to 4 μm thickness using microtome (Leica 




2.18.2 Hematoxylin and eosin (H&E) staining  
 
Formalin-fixed, paraffin-embedded sections were rehydrated by 
immersing in gradient ethanol in the reverse order of dehydration, for 1 
min at each step. Slides were then immersed in filtered-hematoxylin for 
5 min, followed by 0.25% HCl for 3 s. After which, slides were rinsed 
gently in running water for 3 min and then stained with 0.5% aqueous 
eosin for 30 to 40 s. Thereafter, slides were rinsed in distilled water 







2.19.1 Fluorescent microscopy 
 
Cells from phagocytosis assay (on the coverslip in the 12-well plate) 
were fixed with 0.8 ml of 4% paraformaldehyde at RT for 10 min. After 
fixation, 1.0 ml of 1X PBS (supplemented with 3% FBS, 0.5% mouse 
serum and 0.5% rat serum) was added and blocked overnight. 
Macrophages were stained with PE rat α-mouse CD11b for 1 h at RT in 
a humidified chamber, then washed and stained with Hoechst dye 
before mounted onto a glass slide with ProLong® Antifade reagent 
(Thermo Fisher Scientific). Phagocytosis was imaged using Olympus 
IX81 inverted fluorescence microscope with MetaMorph® software (at 
40X objective). Successful phagocytosis was indicated by the 
colocalization of CFSE+ BLCL and CD11b+ macrophage. CFSE+ 
CD11b+ cells were counted over three field of view (FOV) and 
phagocytic index (PI) was computed based on: (% macrophage with at 
least one BLCL) X (average number of BLCL per phagocytic cell). At 





2.19.2 Confocal microscopy 
 
BLCL was cultured overnight on 18 mm poly-L-lysine coated coverslip. 
Cells were then fixed with 4% paraformaldehyde at RT for 10 min 
before staining with α-EBNA TCR-like mAb and rabbit α-β2-
microglobulin antibody for 2 h at RT in a humidified chamber. Cells 
were stained with polyclonal goat α-mouse IgG RPE (Dako) and 
polyclonal goat α-rabbit IgG Alexa Fluor® 488 (Life Technologies) for 1 
h prior to nuclear staining with Hoechst dye. ProLong® Gold Antifade 
mountant was added and images (512 X 512 resolution) were acquired 
at 63X (with oil immersion) using Zeiss LSM 510 confocal microscope 




2.19.3 Digital slide scanner  
 
Slides were scanned using MIRAX MIDI slide scanner (Carl Zeiss). 
H&E slides were scanned in brightfield while slides from phagocytosis 
assay were scanned in the fluorescent channel, with constant gain and 




2.20 Statistical analysis 
 
Statistical analysis including Student’s t-test, Kaplan-Meier survival 
analysis, and Log-rank test was performed using GraphPad Prism. p < 


















3.1 Synopsis  
 
EBNA-1 protein is expressed in all EBV-associated malignancies, and 
thus has been proposed as a good target for therapeutic development. 
Initially, protein degradation was thought to be the determinant of 
EBNA-1 antigen presentation, with studies reporting the presence of 
GAr within the protein auto-inhibiting its proteasomal degradation, 
thereby reducing EBNA-1 presentation [18, 51, 53-55]. However, 
subsequent studies detailed EBNA-1 protein synthesis as the principal 
determinant that underlies the generation of EBNA-1 peptides for 
antigen presentation [56-58].   
 
In this chapter, we determined the effects of GAr on EBNA-1 protein 
translation by comparing EBNA-1 expression in HEK293T cells 
transfected with plasmids encoding full-length EBNA-1 or its GAr-
deleted variant (E1ΔGA). Additionally, we used GFP as a surrogate 
marker for EBNA-1 expression to elucidate the role of GAr in EBNA-1 
protein expression. To test whether EBNA-1 was indeed processed 
and presented on MHC class I molecules, we employed our in-house 
α-EBNA-1 TCR-like mAb to detect surface EBNA-1 pMHC complexes. 
We evaluated the specificity of α-EBNA-1 TCR-like mAb to bind to 
surface EBNA-1 pMHC via peptide pulsing of exogenous peptide and 
conducted staining of EBV-infected BLCL with the antibody to detect 
endogenously derived EBNA-1 pMHC.  
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3.2 Establishing an experimental workflow for EBNA-1 protein 
expression  
 
To determine the role of GAr in EBNA-1 protein expression, plasmids 
encoding the full-length WT EBNA-1 (UniProt accession number: 
P03211) and E1ΔGA90-325 (truncated variant deleted of the GAr) 
sequences were synthesized (Figure 3.1 and Appendix A). Owing to 
the high guanine-cytosine content nature of the nucleotide sequence 
encoding the GAr region, a series of optimization was performed to 
obtain amplicons containing the correct number of GAr (Figure 3.2A). 
As shown in Figure 3.2B, larger bands (in lane 2 and 3) from the PCR 
corresponded to the WT EBNA-1 amplicons, while smaller bands 
observed in lane 4 and 5 corresponded to the E1∆GA amplicons (lane 
3 and 5 were diluted amplicons reflective of their actual size). 
 
To allow the expression of plasmids encoding either WT EBNA-1 or 
E1∆GA construct in the mammalian system (HEK293T), BamHI and 
XbaI restriction sites were incorporated into the 5’ and 3’ ends of each 
construct respectively for cloning into the multiple cloning site of the 
pcDNA™ 3.1 V5-His-TOPO vector. The sequence of WT EBNA-1 and 
E1∆GA within the pcDNA™ 3.1 V5-His-TOPO vector were verified 
using Sanger sequencing prior to transfection. HEK293T cells were 
transfected with plasmids encoding either WT EBNA-1 or E1∆GA and 
harvested at 4 h, day 1, 2, 3 and 5 to check for protein expression via 
Western blot analysis. As shown in Figure 3.2C, the onset of protein 
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expression was different in HEK293T transfected with the two 
constructs. In E1∆GA-transfected cells, a band (between 55 to 70 kDa) 
corresponding to the truncated EBNA-1 (E1ΔGA90-325) protein was 
detected as early as day one post-transfection. 
 
In contrast, a band (between 70 to 100 kDa) corresponding to the full-
length WT EBNA-1 protein was detectable at day 3 post-transfection. 
Besides delayed protein expression, the amount of protein expressed 
by the WT EBNA-1-transfected cells was also relatively lower as 
compared to the E1∆GA-transfected cells. This observation was in 
agreement with an earlier report by Yin et al., which showed that the 
presence of GAr sequence in the WT EBNA-1 protein inhibits its 
synthesis [204]. Furthermore, in WT EBNA-1-transfected cells, a single 
band corresponding to the full-length protein was observed. This is in 
contrast to the multiple smaller bands observed in E1∆GA-transfected 
cells, suggesting possible degradation of the truncated protein, 
corresponding to the reported function of GAr in inhibiting proteasomal-







Figure 3.1: Experimental workflow of EBNA-1 protein expression. Constructs 
encoding full-length WT EBNA-1 and its truncated variant deleted of its GAr 
(E1ΔGA90-325) were abbreviated as WT EBNA-1 and E1ΔGA respectively. 
Sequences encoding WT EBNA-1 and E1ΔGA were synthesized by GenScript and 
subcloned into pcDNA™ 3.1 V5-His-TOPO vector to enable cytomegalovirus 
promoter-driven translation upon transfection into mammalian HEK293T cells. 
Transfected cells were harvested at various time points to check for their protein 




Figure 3.2: Cloning and expression of plasmids encoding WT EBNA-1 and 
E1ΔGA. (A) As the GAr within the WT EBNA-1 is guanine-cytosine-rich, numerous 
optimizations were required for its amplification. (B) WT EBNA-1 and E1ΔGA 
amplicons with BamHI and XbaI restriction sites were cloned into the pCDNA3.1/V5-
His-TOPO vector. The size differences between WT EBNA-1 (lane 2 and 3) and 
E1ΔGA (lane 4 and 5) as observed on a 1% agarose gel, was due to the truncation 
(removal) of the GAr sequence in the E1ΔGA construct. (C) HEK293T cells were 
transfected with plasmids encoding WT EBNA-1 or E1ΔGA and harvested (at 4 h, 
day 1, 2, 3 and 5) for SDS-PAGE and Western blot. Protein expression was 
observed in E1ΔGA-transfected cells as early as day 1 post-transfection, as 
compared to day 3 post-transfection in the WT EBNA-1-transfectants. While a single 
band (between 70 to 100 kDa ladders) was detected in the whole cell lysates of WT 
EBNA-1-transfected cells, multiple smaller bands were observed in E1ΔGA-
transfectants. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 




3.3 Employment of GFP-2A sequence as a surrogate marker for 
protein expression 
 
GFP is a widely used reporter of gene expression in cell and molecular 
biology [205]. However, GFP has also been suggested to affect the 
function and degradation of fusion protein [206]. To overcome the issue 
of direct tagging with GFP, we employed the autocatalytic 2A peptide. 
Derived from the Picornaviridae family, the 2A peptide mediates a 
breakage between the glycine (G) and proline (P) residues via the 
mechanism known as ‘ribosome skipping’ (Figure 3.3A). Specifically, 
the autocatalytic activity is a result of steric hindrance between these 
two residues during peptide bond formation [207, 208]. The insertion of 
GFP-2A into the 5’ ends of WT EBNA-1 and E1∆GA respectively 
(abbreviated as GFP-2A WT EBNA-1 and GFP-2A E1∆GA) permits the 
usage of GFP as a reporter for gene expression without hindering the 
translation of WT EBNA-1 and E1∆GA proteins (Figure 3.3B). 
Importantly, GFP is co-translated as an individual protein and 
expressed at an equimolar concentration with WT EBNA-1 or E1∆GA. 
To confirm that GFP was cloned into the correct reading frame, 
HEK293T cells were transfected with plasmids encoding either GFP-2A 
WT EBNA-1 or GFP-2A E1∆GA and harvested 24 h post-transfection 
for readout via flow cytometry. As shown in Figure 3.3C, GFP 
expression was detected in cells transfected with both constructs, but 




 Figure 3.3: Cloning and expression of plasmids encoding GFP-2A WT 
EBNA-1 and GFP-2A E1ΔGA. (A) DNA and peptide sequences of the 2A 
peptide from foot-and-mouth disease virus (family: Picornaviridae). The DNA 
sequence encodes for a 19 amino acids, with GGG CCC (underlined) coding 
for glycine (G) and proline (P). The red arrow between glycine and proline 
indicates the site of ‘ribosome skipping’ and breakage. The utility of the 2A 
peptide enables the translation of individual proteins flanking the 2A 
sequence, in equimolar concentrations. (B) Schematic illustration of the 
cloning of GFP-2A into plasmid containing WT EBNA-1 (GFP-2A WT EBNA-1) 
and E1ΔGAr (GFP-2A E1∆GA). The utilization of 2A peptide enabled 
equimolar co-translation of GFP and WT EBNA-1 or E1ΔGA, circumventing 
the potential inference of GFP in the translation, folding, trafficking or 
degradation of EBNA-1. (C) HEK293T cells were transfected with either the 
GFP-2A WT EBNA-1 or GFP-2A E1∆GA plasmids, and harvested 24 h post-
transfection. GFP expression was detected in both GFP-2A WT EBNA-1 and 
GFP-2A E1∆GA-transfected cells as compared to their respective non-GFP 




3.4 Elucidating the role of GAr in EBNA-1 expression  
 
With the introduction of GFP into WT EBNA-1 and E1∆GA constructs, 
we next assessed whether GFP expression could function as a 
surrogate marker for EBNA-1 protein expression. To this end, 
HEK293T cells were transiently transfected with either GFP-2A WT 
EBNA-1 or GFP-2A E1∆GA plasmids and harvested over a time course 
of four days for the detection of GFP signal via flow cytometry. 
Transfected cells were additionally processed for intracellular detection 
of EBNA-1 protein.  
 
GAr has been reported to reduce the availability of their fusion partner 
[52, 53, 55]. Consistent with these reports, lower GFP and EBNA-1 
protein expression were observed in cells transfected with GFP-2A WT 
EBNA-1 across all time points in comparison to the GFP-2A E1∆GA-
transfectants (Figure 3.4A and B). Additionally, GFP and EBNA-1 
displayed a similar trend in expression, suggesting that both proteins 
were co-translated and that GFP could be utilized as a marker for 
EBNA-1 protein expression (Figure 3.4C). These observations of 
reduced GFP and EBNA-1 expression provide support to the earlier 
findings that GAr within the WT EBNA-1 protein could function as an 






Figure 3.4: Reduced GFP and EBNA-1 expression in GFP-2A WT 
EBNA-1-transfected cells. HEK293T cells were transfected with 
plasmids encoding either GFP-2A WT EBNA-1 or GFP-2A E1∆GA, and 
harvested to check for their (A) GFP expression and (B) intracellular 
EBNA-1 expression. (C) Percentages of GFP+ and EBNA-1+ cells were 
plotted to compare the protein expression between GFP-2A WT EBNA-
1 and GFP-2A E1∆GA-transfected cells. Cells transfected with the 
plasmid encoding GFP-2A WT EBNA-1 (with the presence of GAr) 
displayed lower GFP and EBNA-1 expression as compared to E1∆GA-




3.5 Detection of surface EBNA-1 presentation using α-EBNA-1 
TCR-like mAb  
 
To determine whether the presence of GAr could impact the antigen 
presentation of EBNA-1 protein, we employed an in-house produced α-
EBNA-1 TCR-like mAb to detect surface pMHC on GFP-2A WT EBNA-
1 and GFP-2A E1∆GA-transfected cells. Details on the generation of α-
EBNA-1 TCR-like mAb, which targets HLA-A*0201-associated EBNA-1 
peptide (FMVFLQTHI) [50] found at the C-terminus region of EBNA-1 
protein, were as previously described (Eio Yating Michelle, Master’s 
thesis). Briefly, mice were immunized with refolded HLA-
A*0201/EBNA-1 (FMVFLQTHI) monomers, and splenocytes were 
magnetically enriched for target-specific, antibody-secreting cells prior 





HEK293T cells were transfected with either GFP-2A WT EBNA-1 or 
GFP-2A E1∆GA encoding plasmids and were harvested for surface 
EBNA-1 pMHC staining with α-EBNA-1 TCR-like mAb. As seen in 
Figure 3.5, no surface EBNA-1 pMHC staining could be seen in both 
transfectants. The lack of surface EBNA-1 pMHC detection was not 
due to the absence of EBNA-1 synthesis and expression, as 
intracellular EBNA-1 staining was observed in both transfected cells, 
with consistently higher protein expression detected in GFP-2A 
E1∆GA-transfectants as compared to GFP-2A WT EBNA-1.  
 
Despite further attempts to stain for surface antigen presentation using 
an alternative transfection cell line HeLa-A2, we were unsuccessful in 
detecting any surface EBNA-1 pMHC with α-EBNA-1 TCR-like mAb 
(data not shown). As such, it remains to be determined whether the 
lack of surface staining was due to the absence of surface EBNA-1 
pMHC presentation or the inability of the α-EBNA-1 TCR-like mAb to 






Figure 3.5: Utility of α-EBNA-1 TCR-like mAb for the detection 
of surface EBNA-1 pMHC. HEK293T cells were transfected with 
either GFP-2A WT or GFP-2A ΔGAr EBNA-1, and harvested on 
day 1, 2, and 3 for flow cytometric analysis. Untransfected cells 
were included as a control. Harvested cells were stained for 
intracellular EBNA-1 and surface EBNA-1 pMHC. Cells were 
stained with mouse IgG1 isotype antibody as an additional negative 
control. While intracellular EBNA-1 proteins were detected in both 
GFP-2A WT and GFP-2A ΔGAr EBNA-1-transfectants, no staining 
for surface EBNA-1 pMHC was observed. Data is representative of 
three independent experiments.   
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3.6 Analyzing the binding activity of α-EBNA-1 TCR-like mAb for 
its pMHC 
 
To ensure that the lack of binding to transfected HEK293T cells as 
observed in Figure 3.5 was not due to the inability of α-EBNA-1 TCR-
like mAb in detecting surface presentation of its cognate EBNA-1 
pMHC, we performed pMHC ELISA and peptide pulsing experiments to 
determine the specificity of the antibody for its target. For pMHC 
ELISA, EBNA-1 peptide (FMVFLQTHI)-bound HLA-A*0201 molecules 
were coated onto ELISA plate prior to the addition of the serially diluted 
α-EBNA-1 TCR-like mAb (with influenza A M1 peptide GILGFVFTL as 
control). α-EBNA-1 TCR-like mAb displayed antibody concentration-
dependent binding to the wells coated with EBNA-1 pMHC monomers, 
while no binding was observed in those wells coated with the influenza 
A M1 pMHC monomers (Figure 3.6A). Data was plotted on GraphPad 
Prism and a KD value of 3.98 nM was obtained, which was consistent 
with surface plasmon resonance data as reported previously by our 




To further verify the specificity of α-EBNA-1 TCR-like mAb, we 
determined its binding to exogenously derived peptides on HLA-
A*0201 cells.  C1R-A2 cells were treated with citric acid to remove pre-
existing surface peptides prior to peptide pulsing with various HLA-
A*02-restricted, pathogen-derived peptides [209]. As shown in Figure 
3.6B, staining was only observed when C1R-A2 cells were pulsed with 
EBNA-1 peptide, but not with other peptides from EBV, 
cytomegalovirus, and influenza A virus, demonstrating that α-EBNA-1 
TCR-like mAb was capable of distinguishing its cognate peptide 
(FMVFLQTHI) from other irrelevant peptides.    
 
We additionally performed pulsing experiments using serially diluted 
peptides with HLA-A*0201, transporter associated with antigen 
processing-deficient T2 cells as a test of the sensitivity of α-EBNA-1 
TCR-like mAb in detecting varying amounts of exogenously loaded 
peptides. Although T2 cells are positive for EBV, their deficiency in 
processing endogenously derived antigens made them suitable for 
studying the presentation of exogenously derived peptides. As seen in 
Figure 3.6C (left histogram), staining was observed when cells were 
pulsed with 1 µM of the EBNA-1 peptide (FMVFLQTHI), and 
concentration-dependent binding was seen with increasing amount of 
FMVFLQTHI pulsed. In contrast, no staining was observed when cells 
were pulsed with the peptide control (NLVPMVATV) from 
cytomegalovirus pp65495-503 (Figure 3.6C, right histogram).      
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Immunofluorescent staining was performed to visualize the binding of 
α-EBNA-1 TCR-like mAb to surface EBNA-1 pMHC. In brief, T2 cells 
were pulsed with either EBNA-1 (FMVFLQTHI) or M1 (GILGFVFTL) 
peptide before staining with α-EBNA-1 TCR-like mAb, followed by 
staining with the fluorescent conjugated secondary antibody. As shown 
in Figure 3.7, staining was observed when cells were pulsed with 
EBNA-1 peptide (FMVFLQTHI), with co-localizing staining with β2-
microglobulin (a subunit of MHC class I). In contrast, staining was not 
observed when cells were pulsed with control peptide GILGFVFTL 
from influenza A M1 protein. Taken together, these data from pMHC 
ELISA and peptide pulsing demonstrated the specificity of α-EBNA-1 
TCR-like mAb for its peptide FMVFLQTHI presented on HLA-A*0201 
molecules, reinforcing the notion that α-EBNA-1 TCR-like mAb 
recognizes pMHC complex similar to a TCR. 
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Figure 3.6: Analyzing the binding activity of α-EBNA-1 TCR-like mAb for its 
pMHC. (A) pMHC ELISA was performed to determine the binding avidity of α-
EBNA-1 TCR-like mAb to its cognate peptide (FMVFLQTHI) in association with 
HLA-A*0201. Antibody concentration-dependent binding was observed with 
EBNA-1 pMHC but not with control peptide GILGFVFTL monomers. Readings 
were measured on a spectrophotometer (at 415 nm) and KD (3.987 nM) was 
determined using GraphPad Prism. (B) C1R-A2 cells were acid-stripped to 
remove pre-existing surface presentation before being pulsed with HLA-A*02-
restricted peptides. Binding was only observed when cells were pulsed with 
EBNA-1 peptide (FMVFLQTHI), but not with other irrelevant peptides. (C) TAP-
deficient T2 cells were pulsed with 10X serially diluted EBNA-1 peptide 
(FMVFLQTHI) or control CMV pp65 peptide (NLVPMVATV) before staining with 
α-EBNA-1 TCR-like mAb. Increased staining was observed on T2 cells when 






Figure 3.7: The employment of α-EBNA-1 TCR-like mAb to 
detect surface EBNA-1 pMHC on pulsed T2 cells. Hoechst dye 
and α-β2-microglobulin antibody staining were performed to 
respectively visualize cell nucleus and MHC class I (with β2-
microglobulin as a subunit). T2 cells were pulsed with either 
FMVFLQTHI (EBNA-1 peptide) or GILGFVFTL (influenza A M1) 
and stained with α-EBNA-1 TCR-like mAb. Staining was observed 
when cells were pulsed with the relevant FMVFLQTHI peptide, 
but not with the control peptide GILGFVFTL. α-EBNA-1 TCR-like 
mAb staining displayed co-localization with β2-microglobulin. 
Scale bar: 20 µm. Images (512 X 512 pixels) were acquired on 
Zeiss LSM 510 confocal microscope software version 2.5 SP2 
under 63X oil immersion objective. Images were overlayed using 
Adobe Photoshop CS6. Blue: nuclear staining with Hoechst dye; 
Red: goat α-mouse IgG RPE (detects α-EBNA-1 TCR-like mAb); 




3.7 Detection of endogenously derived EBNA-1 pMHC using α-
EBNA-1 TCR-like mAb 
 
Given that EBV is prevalent in the humans, we investigated if α-EBNA-
1 TCR-like mAb is capable of detecting surface EBNA-1 pMHC in EBV-
seropositive individuals. Peripheral blood samples were collected from 
HLA-A*0201 EBV-seropositive donors (HLA haplotype and EBV 
serostatus were determined by in-house polymerase chain reaction 
methodology and commercial sequencing). PBMC were obtained by 
Ficoll gradient separation for staining with α-EBNA-1 TCR-like mAb.  
 
We first investigated the staining profiles of α-EBNA-1 TCR-like mAb 
on granulocytes, monocytes, and lymphocytes in the PBMC of a HLA-
A*0201 donor (AM002) (Figure 3.8A). However, none of the three 
immune subsets displayed positive staining with the antibody (Figure 
3.8B). Nonetheless, it should be noted that the frequency of EBV-
infected cell in the peripheral blood can be as low as 1 in 10 million 
peripheral blood lymphocytes [147, 210, 211]. Moreover, taking the 
immunoevasive properties of EBNA-1 into consideration, it should not 
be surprising that no staining was observed with α-EBNA-1 TCR-like 
mAb. This observation is substantiated by an earlier report from 
Wagner et al., which characterized that healthy individuals who were 
latently infected with EBV had no detectable expression of the EBNA-1 
protein [212].  
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Next, we questioned whether our antibody would be capable of 
detecting the presentation of EBNA-1 pMHC on cells naturally infected 
with EBV. Here, we selected BLCL to assess the staining of α-EBNA-1 
TCR-like mAb, as these cells are the in vitro counterpart of EBV-
infected B cells in humans, expressing all of the EBV latent products, 
including EBNA-1 (Table 1.1, latency III program). To start, HLA-
A*0201 PBMC from the same individual (AM002) was isolated and 
immortalized in vitro to generate BLCL. Briefly, B95-8 EBV supernatant 
was added to the PBMC, and macroscopic cell clumps were observed 
two weeks post-infection.  
 
With the establishment of a stable BLCL after 30 days of culture, we 
proceeded to stain the newly generated cell line (AM002 BLCL) with 
our α-EBNA-1 TCR-like mAb. In contrast to the lack of staining with 
PBMC (Figure 3.8B), positive staining was observed with α-EBNA-1 
TCR-like mAb on AM002 BLCL generated from the same PBMC 
(Figure 3.8C). As peptide pulsing was not utilized, the detection of 
surface EBNA-1 pMHC with α-EBNA-1 TCR-like mAb demonstrated 
the existence of endogenously derived EBNA-1 pMHC on BLCL, and 
that α-EBNA-1 TCR-like mAb could differentiate BLCL from the PBMC 




Figure 3.8: Staining of surface EBNA-1 pMHC was observed on BLCL but not 
on matching PBMC. PBMC was obtained from HLA-A*0201 donor and stained 
with α-EBNA-1 TCR-like mAb. (A) Cells were plotted on FSC versus SSC to 
differentiate granulocytes, monocytes and lymphocytes. (B and C) While no 
staining was observed on the different immune subsets (based on parent gates in 
Figure 3.8A), a distinct staining for surface EBNA-1 pMHC was observed on BLCL 
generated from EBV in vitro infection of the PBMC. HLA-A haplotype of BLCLs was 





3.8 Restriction and specificity of α-EBNA-1 TCR-like mAb  
 
With the validation on the capability of α-EBNA-1 TCR-like mAb to 
detect endogenously derived EBNA-1 pMHC, we further verified the 
restriction of the antibody for HLA-A*0201 and its specificity for EBV. 
As shown in Figure 3.9, staining was observed with EBV-infected, 
HLA-A*0201 BLCL (CF986) but not with non-HLA-A*0201 BLCL 
(CF888),  illustrating that the recognition of surface EBNA-1 pMHC by 
α-EBNA-1 TCR-like mAb was only relevant in the context of HLA-
A*0201 (HLA-A*0201-restricted).  
 
To demonstrate the specificity of α-EBNA-1 TCR-like mAb for EBV, we 
stained EBV‒ HLA-A*0201 HEK293T cells with α-EBNA-1 TCR-like 
mAb. In contrast to EBV+ CF986 BLCL, HEK293T are EBV‒ and do not 
express EBNA-1, and thus these cells were not stained positive for 
surface EBNA-1 pMHC (Appendix B - intracellular EBNA-1 staining 
was performed to verify the presence of EBV in HEK293T and CF986). 
Similarly, no staining was observed with EBV‒ and non-HLA-A*0201 BL 
cell line (Ramos). Altogether, our data demonstrated HLA-A*0201-
restriction and EBV-specific characteristics of α-EBNA-1 TCR-like mAb 






Figure 3.9: α-EBNA-1 TCR-like mAb can detect endogenously 
derived, surface EBNA-1 pMHC on HLA-A*0201 BLCL. Staining 
with α-EBNA-1 TCR-like mAb was observed on HLA-A*0201 and 
EBV+ BLCL (CF986), but not on EBV‒ HEK293T, HLA-A*02‒ CF888 
and EBV‒HLA-A*02‒ Ramos. Mouse IgG1 isotype antibody was 
used as a negative control. In addition, intracellular EBNA-1 staining 
was conducted to verify the presence of EBV in HEK293T and 




We next visualized the staining of endogenously derived EBNA-1 on 
BLCL via confocal microscopy. Staining for surface EBNA-1 pMHC 
was observed with α-EBNA-1 TCR-like mAb on BLCL in comparison to 
isotype control antibody, with co-localization of EBNA-1 pMHC with β2-
microglobulin staining (Figure 3.10). Taken together, the use of α-
EBNA-1 TCR-like mAb enabled the discernment of BLCL versus 
PBMC from which they were derived. More importantly, the 
employment of α-EBNA-1 TCR-like mAb permitted the detection of 
both exogenously-pulsed and endogenously derived peptides, 
highlighting its capability of binding to surface EBNA-1 pMHC in the 




Figure 3.10: Immunofluorescent staining revealed surface 
EBNA-1 pMHC of endogenous origin. HLA-A*0201 BLCL was 
fixed onto coverslip and stained with α-EBNA-1 TCR-like mAb and 
α-β2-microglobulin antibody. Staining of endogenous EBNA-1 
pMHC was observed with the α-EBNA-1 TCR-like mAb, co-
localizing with the β2-microglobulin. Mouse IgG1 isotype antibody 
was used as a negative control. Scale bar: 20 µm. Images (512 X 
512 pixels) were acquired on Zeiss LSM 510 confocal microscope 
software version 2.5 SP2 under 63X oil immersion objective. 
Images were overlayed using Adobe Photoshop CS6. Blue: 
nuclear staining with Hoechst dye; Red: goat α-mouse IgG RPE 
(detects α-EBNA-1 TCR-like mAb); Green: goat α-rabbit IgG Alexa 
Fluor® 488 (detects β2-microglobulin).  
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3.9 α-EBNA-1 TCR-like mAb can bind to BLCLs despite their 
intrinsic heterogeneity  
 
BLCLs are EBV-infected B cells which are heterogeneous with respect 
to their size, morphology, and immunophenotype. Using AM001 BLCL 
and CF986 BLCL as examples, we could observe apparent differences 
in terms of size under the microscope (Figure 3.11A), as well as 
forward scatter (FSC, size) and side scatter (SSC, granularity) profiles 
via flow cytometry (Figure 3.11B). Both AM001 and CF986 exhibited 
villous membrane projections, which are characteristic of BLCL, as 
compared to a more rounded morphology of Raji (B lymphoma cell line) 
[213]. In order to further characterize these BLCLs, multicolor flow 





Figure 3.11: Morphological heterogeneity in BLCLs. (A) Fluorescent 
microscopy of BLCLs (AM001 and CF986) and BL cell line (Raji). Cells were 
stained with Hoechst dye (Blue) for nuclear staining. Villous membrane 
projections, as observed in both AM001 and CF986, are characteristic of the 
immunoblastic and activated status of the BLCLs. In comparison, Raji cells 
displayed a more rounded morphology (Images were courtesy of Ms. Lai 
Junyun). (B) Forward (FSC) and side (SSC) scatter plot on a flow cytometer also 









As shown in Table 3.1, all BLCLs were found to be negative for non-B 
cell markers such as CD3 (T cells), CD34 (hematopoietic progenitor 
cells), and CD56 (NK cells). While the expression of CD10 (early B cell 
marker) and CD138 (plasma cell marker) was not detected, the 
expression of B cell lineage markers such as CD19, CD20, and CD23 
was observed in all the BLCLs. In addition, the expression of co-
stimulatory molecules (CD40 and CD86) and activated markers (CD38) 
were also found in all BLCLs tested. However, markers such as CD27, 
IgM, and IgD varied in their expression, highlighting the heterogeneity 
between BLCLs. Notably, the expression of prototypic death receptor 
(CD95) was detected, consistent with the reported upregulation of 
CD95 upon EBV infection [214-216].  
 
Despite the observed morphological and immunophenotypic 
heterogeneity between BLCLs, the fact that all BLCLs are latently 
infected with EBV indicates a common feature among these cells. To 
show the similarity between the BLCLs, immunoblotting for EBV latent 
proteins was conducted. As shown in Figure 3.12, the expression of 
EBNA-1, LMP1, and EBNA-2, though at varying levels, were observed 
in all the BLCLs, but not in EBV‒ BL cell line (BJAB). In particular, the 
expression of EBNA-2 which defines EBV latency III gene expression 
profile was found in all the BLCLs, consistent with previous reports 







Figure 3.12: Immunoblot detection of EBV latent proteins in 
BLCLs. Immunoblotting was performed to determine the latency profile 
of BLCLs. The expression of EBNA-1, LMP1 and EBNA-2 were 
detected in all the BLCLs. All cells displayed latency III profile based on 
the characteristic expression of EBNA-2. Housekeeping gene GAPDH 
was used as a loading control. EBV‒ human BL cell line (BJAB) was 
used as a negative control.  
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With the expression of EBV latent proteins shown in the heterogeneous 
BLCLs, we next assessed whether α-EBNA-1 TCR-like mAb could 
detect its surface target on a panel of different donor-derived HLA-
A*0201 BLCLs. For comparison purposes, we included addition 
staining with another in-house produced antibody (α-LMP1 TCR-like 
mAb) which recognizes surface EBV LMP1 pMHC presented on HLA-
A*0201 molecules. As shown in Figure 3.13A, a significant higher 
staining was observed with α-EBNA-1 TCR-like mAb as compared to 
α-LMP1 TCR-like mAb (Appendix C), and this observation was 





 Figure 3.13: α-EBNA-1 TCR-like mAb detects endogenous surface EBNA-1 
pMHC between different donor-derived HLA-A*0201 BLCLs despite their 
heterogeneity. (A) A collection of HLA-A*0201 PBMC-derived BLCLs was obtained 
from different donors, harvested and stained with α-EBNA-1 TCR-like mAb and α-
LMP1 TCR-like mAb (another in-house produced antibody specific for EBV surface 
LMP1 pMHC). Mouse IgG1 isotype control and α-HLA-A2 were used as the 
negative and positive control respectively (Appendix C). Despite the heterogeneity 
between BLCLs, endogenously derived surface EBNA-1 and LMP1 pMHC were 
observed, with a general trend of higher surface EBNA-1 pMHC staining detected in 
all HLA-A*0201 BLCLs (p = 0.0005). (B) Graphical representation of surface EBNA-
1: LMP1 pMHC staining of each BLCL presented in Figure 3.13A. Higher nMFI 
values were consistently observed with α-EBNA-1 TCR-like mAb (as compared to α-
LMP1 TCR-like mAb) in each of the HLA-A*0201 BLCLs. nMFI values were 
obtained by dividing α-EBNA-1 (or LMP1) TCR-like mAb MFI readings by its 
respective mouse IgG1 isotype control MFI. Values are expressed as mean ± SD.  





3.10 Constitutive surface presentation of EBNA-1 pMHC on BLCLs 
 
Previously, α-EBNA-1 TCR-like mAb was employed to study the 
antigen presentation of EBNA-1 but its therapeutic application was left 
unexplored. Before assessing the therapeutic potential of α-EBNA-1 
TCR-like mAb, it is important to validate the availability of surface 
EBNA-1 pMHC on BLCLs, as that will impact the accessibility of the 
antibody to target the BLCLs. To understand the kinetics of EBNA-1 
pMHC surface presentation on HLA-A*0201 BLCLs, we evaluated α-
EBNA-1 TCR-like mAb staining on BLCLs daily, for up to seven days. 
As shown in Figure 3.14A, EBNA-1 pMHC was consistently detected 
on CM462 BLCL during all of the assessed time points. We expanded 
our kinetic study to include a panel of HLA-A*0201 BLCLs; despite 
fluctuations in surface presentation (Figure 3.14B), surface EBNA-1 
pMHC was detected in all of the tested BLCLs (Appendix D). 
Furthermore, surface EBNA-1 pMHC was detected repeatedly on 
BLCLs despite multiple freeze-thaw cycles (data not shown). Based on 
the constitutive presentation of surface EBNA-1 pMHC on BLCLs and 
the capability of α-EBNA-1 TCR-like mAb to detect endogenous EBNA-
1 pMHC, our data suggested on the potential utility of α-EBNA-1 TCR-





Figure 3.14: Constitutive surface presentation of EBNA-1 on HLA-A*0201 
BLCLs. HLA-A*0201 BLCLs were stained with  α-EBNA-1 TCR-like mAb daily, for 
up to one week. (A) Using CM462 (HLA-A*0201 BLCL) as an illustration, surface 
EBNA-1 pMHC was constitutively detected in all seven days. (B) Despite 
fluctuations in the staining profiles of the assessed BLCLs, their levels of surface 
EBNA-1 pMHC were consistently observed and well-separated from their 


















4.1 Synopsis  
 
EBV-associated B cell lymphoproliferative disorders like PTLD occur in 
immunosuppressed transplant recipients when immunological 
suppression of EBV is weakened due to the suppression of T cell 
immunity. To assess the therapeutic potential of α-EBNA-1 TCR-like 
mAb in a context relevant to PTLD, we employed NSG mice to 
simulate immunosuppressed individuals with B cell lymphoproliferation. 
Having an immunodeficient background, NSG mice can support the 
engraftment of BLCL, permitting uncontrolled B cell lymphoproliferation 
as observed in PTLD patients. In this chapter, we assessed the weekly 
administration of α-EBNA-1 TCR-like mAb on disease manifestations 
(B cell lymphoproliferation) in various organs of the mice. Furthermore, 
we performed apoptosis assay and phagocytosis assay to dissect the 
in vitro effects of α-EBNA-1 TCR-like mAb on EBV-infected B cells. In 
addition, we generated a FcγR-null binding variant of the antibody to 
further verify whether α-EBNA-1 TCR-like mAb-mediated phagocytosis 
is Fc-dependent mechanism. 
 
 
4.2 Determining a treatment regimen for α-EBNA-1 TCR-like mAb 
 
In order to define the treatment regimen, a batch of BLCL-injected NSG 
mice was euthanized one week post-BLCL injection, while others were 
set aside for the monitoring of disease progression. While no abnormal 
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pathology was observed in the organs of the mice that were euthanized 
one week post-BLCL injection (Figure 4.1), flow cytometric analysis 
revealed the presence of hCD45+ cells in the bone marrows, peripheral 
blood, kidneys, livers, lungs, and spleens of these mice one week post-
BLCL injection (Figure 4.2A). These cells were further confirmed to 
express CD19, indicating successful BLCL engraftment (Figure 4.2B).  
 
In a separate batch of mice that were kept for disease monitoring, 
signs of terminal disease were observed at day 21. Upon euthanasia, 
mass lesions were seen in the spleens and livers, in addition to 
splenomegaly and pale kidneys (Figure 4.3). Importantly, these 
observations were similar to several of the clinical manifestations found 
in PTLD patients, suggesting that this mouse xenograft model is 
capable of recapitulating some features of the disease. No disease 
manifestation was observed in mice injected with control media. With 
the defined disease progression and pathological manifestations, we 
next proceeded to test the in vivo therapeutic efficacy of α-EBNA-1 





Figure 4.1: No abnormal pathology was observed in day 7 BLCL-
injected mouse xenograft model. Immunodeficient NSG mice were 
injected with 2 X 106 BLCL (or control media), and euthanized 7 days 
thereafter. Compared to RPMI-injected mice (n=2), no observable 
disease manifestation was seen in BLCL-injected mice (n=3). Images 








Figure 4.2: Detection of BLCL in the various organs at day 7 
BLCL-injected mice. On top of gross anatomy examination, organs 
of BLCL-injected mice were processed and stained for hCD45 and 
CD19 prior to flow cytometric analysis. (A)  Based on hCD45 vs FSC 
plot, the presence of hCD45 cells, though at very low percentages 
were detected in the peripheral bloods, livers, lungs, and spleens. (B) 
When these cells were subsequently checked for CD19 expression, 










Figure 4.3: Disease manifestations were observed in BLCL-
injected mouse xenograft model. Pathological manifestations in the 
spleen, liver and kidney were observed in mice 3 weeks post-BLCL 
injection (n=4). Mass lesions (tumor spots) were present in the spleen, 
liver and kidney. In addition, splenomegaly (the enlargement of the 
spleen) and pale kidneys were observed in the BLCL-injected mice 
(Top panel), displaying some of the clinical features PTLD in 
transplant recipients.  Arrows indicate the mass lesions observed on 
the liver.   
 
Figure 4.4: Schematic illustration of α-EBNA-1 TCR-like mAb 
treatment regimen. Two million (2 X 106) BLCL was injected into 15 
weeks old NSG mice via the tail vein. Mice were treated weekly, with 
either a single dose of α-EBNA-1 TCR-like mAb (300 µg/injection) or 
isotype control antibody from week 16 onwards. Euthanasia was 
performed when weight loss of 20% or signs of disease were 
observed. Organs were then harvested for flow cytometric analysis and 




4.3  α-EBNA-1 TCR-like mAb treatment ameliorates disease in vivo 
 
As shown in Figure 4.5A, despite the fluctuations in the body weight of 
mice treated with α-EBNA-1 TCR-like mAb, they exhibited a delayed 
weight loss as compared to mice treated with mouse IgG1 isotype 
control antibody. Mice treated with another in-house produced TCR-like 
mAb specific for EBV LMP1 (α-LMP1 TCR-like mAb) did not exhibit any 
delayed weight loss. Based on Kaplan-Meier analysis, α-EBNA-1 TCR-
like mAb treatment (p = 0.0098) significantly prolonged the survival of 
treated mice (Figure 4.5B). In contrast, all mice that were treated with 
the mouse IgG1 isotype control antibody or α-LMP1 TCR-like mAb 
displayed signs of disease (20% weight loss and/or moribund) and had 
to be euthanized by day 28.  
 
Based on gross anatomy, no obvious disease manifestation was 
observed in the α-EBNA-1 TCR-like mAb-treated mice, while mass 
lesions were seen in the spleens of the isotype control antibody-treated 
mice (Figure 4.6A and Appendix E). Furthermore, H&E staining 
revealed a uniform appearance in the spleen histology of α-EBNA-1 
TCR-like mAb-treated mouse, and this is in contrast to the regions of 
irregularity shown in the spleen of the isotype control antibody-treated 
mouse (Figure 4.6B). To assess the treatment effect in a more 
quantitative manner, we analyzed the percentages of hCD45+ 
infiltration within organs via flow cytometry. As seen in Figure 4.6C and 
Appendix E, a stark decrease in BLCL infiltration was observed in the 
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spleen of α-EBNA-1 TCR-like mAb-treated mice as compared to that of 
the isotype control antibody-treated mice.  
 
The amelioration of disease manifestations was also evident in the liver 
of the α-EBNA-1 TCR-like mAb-treated mice (Figure 4.7A and 
Appendix E). In mice treated with the isotype control antibody, multiple 
mass lesions were observed all over the liver. Consistent with the 
gross anatomy, H&E staining revealed the infiltration of small, round 
and monomorphic cells with hyperchromatic staining (Figure 4.7B). 
Digitally-highlighted image of the liver histology further revealed the 
severe disruption of the liver parenchymal architecture in the isotype 
control antibody-treated mice, but in the α-EBNA-1 TCR-like mAb-
treated mice, the tissue morphology was well-preserved. Coherently, 
flow cytometric analysis of the liver showed that treatment with the α-
EBNA-1 TCR-like mAb resulted in a reduction of hCD45+ cells 
infiltration (6.51% versus 1.49%) when compared to isotype control 




Despite the improvements in disease outcome in the spleens and livers 
of α-EBNA-1 TCR-like mAb-treated mice, such effect was not observed 
in the kidneys. Based on the staining for CD45 and CD19, a 
comparable percentage of kidney infiltration (11.7% versus 10.3%) was 
observed regardless of antibody treatment (Figure 4.8A and B). 
Furthermore, in mice which were euthanized at day 22, 33, and 44, an 
increasing amount of BLCL infiltration into the kidneys was observed 
(Figure 4.8C)  
 
Taken together, our data demonstrated that the administration of a 
single dose of α-EBNA-1 TCR-like mAb weekly can decrease tumor 
burden and bring about therapeutic effects in the spleen and liver, 
providing a possible explanation for the observed delayed weight loss 




Figure 4.5: α-EBNA-1 TCR-like mAb treatment delayed weight loss and 
prolonged survival in treated mice. (A) Body weight and (B) Kaplan-Meier survival 
analysis of mice treated with α-EBNA-1 TCR-like mAb or mouse IgG1 isotype control 
antibody. Treatment with another in-house produced α-EBV TCR-like mAb (α-LMP1 
TCR-like mAb) was included for comparison. Although an overall reduction in body 
weight was observed in the α-EBNA-1 TCR-like mAb-treated mice, the extent of 
weight loss was much lesser than mouse IgG1 isotype control antibody and α-LMP1 
TCR-like mAb-treated counterparts. In addition, Kaplan-Meier survival plot also 
demonstrated that α-EBNA-1 TCR-like mAb-treated mice exhibited prolonged survival 






Figure 4.6: α-EBNA-1 TCR-like mAb ameliorated disease 
manifestation in the spleens of treated mice. 
Representative (A) gross anatomy, (B) H&E staining, and (C) 
flow cytometry profiles of spleens harvested from treated 
mice. Mass lesions were observed in the spleen of mouse 
IgG1 isotype control antibody-treated mice (n=3), but not that 
of the α-EBNA-1 TCR-like mAb-treated mice (n=4). H&E 
staining showed regions of irregularity in the spleen sections 
of the isotype control antibody-treated mice, which was in 
contrast to the uniform appearance seen in the α-EBNA-1 
TCR-like mAb-treated mice. Furthermore, flow cytometric 
analysis showed no infiltration of hCD45 cells in the spleen of 
the α-EBNA-1 TCR-like mAb-treated mouse, while mouse 
treated with the IgG1 isotype control antibody had an 







Figure 4.7: α-EBNA-1 TCR-like mAb ameliorated disease manifestation in 
the livers of treated mice. (A and D) In terms of gross anatomy, multiple 
mass lesions were observed in the liver of IgG1 isotype control-treated mice 
(n=3), but not the mice treated with α-EBNA-1 TCR-like mAb (n=4). (B and E) 
Consistent with the gross anatomy observation, H&E staining on the liver 
section of IgG1 isotype control-treated mice revealed the infiltration of small, 
round and monomorphic cells with hyperchromatic nuclear staining. Mass 
lesions were digitally highlighted using Adobe Photoshop CS6, and a 10X 
magnification of the liver section together illustrated the disruption of the liver 
parenchymal architecture. On the other hand, no obvious pathology was 
observed in α-EBNA-1 TCR-like mAb-treated mice. Coherently, flow cytometry 
plot of hCD45 versus mCD45 dot plot also showed higher percentage of hCD45 
infiltration in IgG1 isotype control-treated mouse (C, 6.51%), while reduced 
BLCL infiltration was observed in α-EBNA-1 TCR-like mAb-treated mouse (F, 




 Figure 4.8: Infiltration of BLCL into the kidneys was observed regardless 
of the treatment. (A) Flow cytometric illustration of hCD45 (human leukocyte 
marker) versus mCD45.1 (mouse CD45 marker) dot plot showed similar 
percentage of BLCL infiltration into the kidneys of mice treated with mouse 
IgG1 isotype control antibody or α-EBNA-1 TCR-like mAb. (B) Based on the 
parent gating in Figure 4.8A, gated cells were confirmed to be of B cell lineage, 
expressing the surface marker CD19. (C) α-EBNA-1 TCR-like mAb-treated 
mice were euthanized at day 22, 33, and 44 to check for the percentage of 
BLCL infiltration into various organs. An increasing severity of BLCL infiltration 
into the kidneys was observed in mice euthanized at later time points. Days 




4.4 α-EBNA-1 TCR-like mAb induces early apoptosis in BLCL 
 
Unconjugated antibodies can engender a number of effector functions 
such as CDC, ADCC, antibody-mediated phagocytosis and the direct 
induction of apoptosis [123, 125, 132-135]. As mice treated with the α-
EBNA-1 TCR-like mAb displayed delayed weight loss and prolonged 
survival, we next sought to examine the underlying mechanism(s) for 
this observed therapeutic effect.  
 
As NSG mice are devoid of B cells, T cells, NK cells and the hemolytic 
complement system [160], the mechanisms of which the α-EBNA-1 
TCR-like mAb could elicit were narrowed down to the direct induction 
of apoptosis and antibody-mediated phagocytosis. To test if the 
treatment of α-EBNA-1 TCR-like mAb can induce the apoptosis in vitro, 





Exposed phosphatidylserine (PS) on the outer leaflet of the cell 
membrane is an indicator of early stage apoptosis. As such, we 
assessed the amount of surface PS on BLCL via the preferentially 
binding of annexin V to exposed PS. Staining with fluorescent-
conjugated annexin V showed that treatment with the α-EBNA-1 TCR-
like mAb upregulated the expression of PS at 6 h and 24 h, with a 
greater upregulation of PS when 10 µg of α-EBNA-1 TCR-like mAb 
was added (Figure 4.9A).   
 
In late apoptotic cells, the integrity of the cell membrane is 
compromised and no longer able to exclude DNA-binding dye. We thus 
used the DNA-binding dye 7-AAD as an indicator of late stage 
apoptosis. As shown in Figure 4.9B, no staining with 7-AAD was 
observed in BLCL treated with α-EBNA-1 TCR-like mAb. These data 
demonstrated that α-EBNA-1 TCR-like mAb treatment could directly 






Figure 4.9: Treatment with α-EBNA-1 TCR-like mAb resulted 
in the induction of early stage apoptosis in vitro. To 
elucidate if α-EBNA-1 TCR-like mAb could elicit direct 
apoptosis, BLCL was treated with 1 µg and 10 µg of the 
antibody and harvested 6 h and 24 h later to check for 
apoptosis. (A) Annexin V and (B) 7-AAD staining were used as 
indicators of early and late stage apoptosis respectively. The 
induction of early stage apoptosis was observed in BLCL treated 
with α-EBNA-1 TCR-like mAb (1 µg and 10 µg) at both 6 h and 
24 h time points. On the other hand, the induction of late stage 
apoptosis was not observed at both of the assessed time points 




4.5 α-EBNA-1 TCR-like mAb promotes the phagocytosis of BLCL 
in vitro   
 
As professional phagocytes of the innate immune system, 
macrophages have been reportedly capable of phagocytosing tumor 
cells [219-221]. These cells are present in the NSG mice and have 
been shown by many to exhibit functional phagocytic activities [219, 
222, 223]. To find out if α-EBNA-1 TCR-like mAb could facilitate the 
phagocytosis of BLCL by macrophages, in vitro phagocytosis assay 
was conducted.  
 
Briefly, BLCL was labeled with CFSE and treated with the antibodies 
prior to the assay. Macrophages were stained with PE-CD11b for flow 
cytometric analysis, and PE+CFSE+ cells in the second quadrant (Q2) 
were defined as the successful uptake of CFSE-labeled BLCL by the 
macrophages. When BLCL was incubated with α-EBNA-1 TCR-like 
mAb for 3 h prior to phagocytosis, 4.3% of PE+CFSE+ cells was 
observed (Figure 4.10A). The enhancement of phagocytosis upon α-
EBNA-1 TCR-like mAb treatment was higher than the basal levels of 
phagocytosis observed when no antibody or mouse IgG1 isotype 
control antibody was added. Similarly, the enhancement of 
phagocytosis was also observed when BLCL was pre-incubated with 
the α-EBNA-1 TCR-like mAb for 24 h prior to the phagocytosis assay 




To ensure that the observed PE+CFSE+ data acquired on flow 
cytometry were true phagocytic events and not cell aggregates with 
non-specific staining, fluorescent microscopy was used to visualize the 
phagocytosed BLCL within macrophages. As seen in Figure 4.11, 
different phases of phagocytosis such as contact and engulfment were 
observed with α-EBNA-1 TCR-like mAb treatment.  
 
As an alternative approach to quantify phagocytosis, phagocytic index 
was used to enumerate phagocytosis based on the manual counting of 
PE+CFSE+ cells. As compared to mouse IgG1 isotype control, the 
treatment with α-EBNA-1 TCR-like mAb promoted phagocytosis at both 
3 h and 24 h time points, consistent with the flow cytometry data 




Figure 4.10: α-EBNA-1 TCR-like mAb treatment enhanced the 
phagocytosis of BLCL (flow cytometry). Flow cytometry was used to 
elucidate the effects of α-EBNA-1 TCR-like mAb treatment on 
phagocytosis. Percentage of CD11b+CFSE+ cells in quadrant 2 (Q2) 
denotes successful phagocytosis. Compared to no antibody and mouse 
IgG1 isotype control treatment, BLCL incubated with α-EBNA-1 TCR-like 
mAb for (A) 3 h and (B) 24 h prior to phagocytosis enhanced their uptake 
by the CD11b+ macrophages. Data is representative of two independent 











Figure 4.11: Different phases of phagocytosis were observed 
upon α-EBNA-1 TCR-like mAb treatment. Phagocytosis assay was 
performed to visualize the ability of α-EBNA-1 TCR-like mAb in 
facilitating phagocytosis. Immunofluorescent staining showed the 
engagement and engulfment of BLCL (green) by a macrophage (red) 





Figure 4.12: α-EBNA-1 TCR-like mAb treatment enhanced the 
phagocytosis of BLCL (fluorescent microscopy). (A) Immunofluorescent 
staining was used as an alternative methodology for phagocytosis assay 
quantification. The enhancement of phagocytosis upon α-EBNA-1 TCR-like 
mAb treatment was observed at both 3 h and 24 h time points. White arrows 
were used to indicate the relative amount of phagocytosis. (B) Phagocytic 
index (%) was calculated based on visual scoring of CD11b+CFSE+ cells over 
three FOV. Statistical significances for 3 h and 24 h α-EBNA-1 TCR-like mAb 
incubation were p = 0.019 and p = 0.0169 respectively (unpaired Student’s t-




4.6 Fc-dependent mechanism of α-EBNA-1 TCR-like mAb-
mediated phagocytosis  
 
As antibody-mediated phagocytosis requires Fc receptor binding, 
antibody variant with a mutation in the Fc portion that abrogates Fc 
receptor binding will abolish phagocytosis. As such, to investigate 
whether α-EBNA-1 TCR-like mAb-mediated phagocytosis was Fc-
dependent, we generated a FcγR-null binding variant of the antibody, 
denoted as α-EBNA-1 TCR-like mAb (D265A) (Figure 4.13A).  
 
As shown in Figure 4.13B, the FcγR-null binding variant of α-EBNA-1 
TCR-like mAb displayed a similar profile as the unmodified antibody on 
a SDS-PAGE gel, with a band observed (between 150 kDa to 250 kDa) 
corresponding to the intact antibody in non-reducing conditions, and 
two bands corresponding to the heavy (at 50 kDa) and light chains (at 
25 kDa) of an antibody under reducing condition. To show that the 
mutation on α-EBNA-1 TCR-like mAb had no impact on its binding 
capability, flow cytometric analysis was performed to assess the 
staining for EBNA-1 pMHC on HLA-A*02 BLCL. Indeed, α-EBNA-1 
TCR-like mAb (D265A) demonstrated equivalent binding profile as the 
unmodified antibody (Figure 4.13C).  
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To assess the functionality of α-EBNA-1 TCR-like mAb (D265A), 
phagocytosis assay was performed to compare the ability of the FcγR-
null binding variant (D265A) and its unmodified antibody in mediating 
phagocytosis.  As seen in Figure 4.14, while the unmodified α-EBNA-1 
TCR-like mAb had an observed 11.3% PE+CFSE+ cells, treatment with 
the FcγR-null binding variant (D265A) greatly abrogated phagocytosis 
(4.42%) to levels comparable to the no antibody (5.78%) and mouse 
IgG1 isotype (6.92%) treatment controls. Taken together, our data 
validated the capability of the α-EBNA-1 TCR-like mAb in promoting 
phagocytosis, and further affirmed the involvement of Fc receptor 












Figure 4.13: Characterization of the FcγR-null binding variant (D265A) of 
α-EBNA-1 TCR-like mAb. (A) Schematic illustration of the site-directed 
mutagenesis of aspartic acid at position 265 to alanine in the CH2 domain of 
the antibody, generating antibody variant incapable of FcγR binding. (B) 
Purified FcγR-null binding variant (D265A) showed no discernible difference 
from the unmodified α-EBNA-1 TCR-like mAb under both non-reducing and 
reducing conditions on a SDS-PAGE gel. (C) Flow cytometry analysis was 
performed to compare the binding of FcγR-null binding variant (D265A) with its 
unmodified α-EBNA-1 TCR-like mAb. Histogram plot showed that both 





Figure 4.14: Abolishment of phagocytosis with FcγR-null binding 
variant (D265A) of the α-EBNA-1 TCR-like mAb. Phagocytosis assay was 
performed to confirm the requirement of FcγR in eliciting antibody-mediated 
phagocytosis. Using the unmodified α-EBNA-1 TCR-like mAb as a positive 
control, enhanced phagocytosis (11.3%) was observed when compared to 
no antibody (5.78%) and mouse IgG1 isotype control (6.92%). Phagocytosis 
was abolished (4.42%) when the FcγR-null binding variant (D265A) of α-


















5.1 Synopsis  
 
In this chapter, we described the generation of a novel autologous 
humanized mouse model of EBV-associated disease, which can serve 
as a potential preclinical model for therapeutic assessment. In this 
setup, NSG mice were employed to support the reconstitution of a 
human hematoimmune system. In parallel, autologous BLCLs were 
generated in vitro and injected into NSG mice reconstituted with CD34+ 
HPCs from the same donor, thereby establishing a syngeneic model. 
We performed in vitro EBV infection with various samples such as cord 
blood and fetal organs (liver, bone marrow and spleen) to evaluate 
their ability to generate BLCL for the autologous humanized mouse 
model. To improve the reconstitution of human immune cells in our 
system, we further employed HDI of plasmids encoding human 
cytokines to augment the development of specific immune cell types.  
 
 
5.2 Establishing a humanized mouse model engrafted with 
autologous cord blood-derived BLCL 
 
The standard humanized mouse model of EBV infection involves the 
injection of EBV supernatant to infect de novo reconstituted human B 
cells, supporting EBV infection in vivo (Figure 1.6). However, this 
approach poses inconsistency in the efficiency of in vivo EBV infection 
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due to varied numbers of reconstituted human B cells available for 
infection within each mouse.  
 
To improve the model, we modified the current approach by infecting B 
cells with EBV in vitro using cord blood-derived B cells from the 
negative fraction of CD34+ selection. Upon the obtainment of stabilized 
BLCL after six weeks of passaging, we injected a fixed number of 
BLCL into 12 weeks old humanized mouse reconstituted with matching 
HPCs from the same donor, establishing an orthotopic and autologous 
humanized mouse model (Figure 5.1). This approach would enable us 
to inject a precise number of BLCL, achieving the desired disease 
outcome. In addition, as BLCL was generated in vitro, these cells could 
be thoroughly characterized and tested for their sensitivity to 
therapeutics in vitro. 
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As per normal de novo generation of the human lymphoid immune cells 
in the humanized mouse, the reconstitution of human immune cells 
such as CD45, CD3, CD4, CD8, and CD19 were observed (Figure 
5.2). To delineate the development of human immune cells in this 
autologous humanized mouse model, weekly facial bleeding was 
performed for flow cytometric immunophenotyping over the course of 
18 weeks.  
 
As seen in Figure 5.3A, hCD45+ cells were detected in the peripheral 
blood of the autologous humanized mice for the entire 18 weeks, albeit 
with decreasing chimerism over time. Within these hCD45+ cells, a 
decreasing percentage of CD19+ B cells reconstitution was 
accompanied by the observed increment in CD3+ T cells (Figure 5.3B). 
In terms of CD4/CD8 T cell ratio, a general trend of increasing CD4+ T 
cells was observed when compared to CD8+ T cells (Figure 5.3D-F).  
 
In humanized mice injected with autologous BLCL, no obvious 
pathological manifestation was observed upon euthanasia (data not 
shown). While these mice had larger spleens, they were not 
significantly larger than those from the non-injected humanized control 
mice (Figure 5.4A). However, mice that were injected with autologous 
BLCL displayed reduced weight gain over the time course and were 
therefore suggested to be less healthy than the control mice (p < 




Figure 5.1: The development of a novel humanized mouse model for 
preclinical testing. The current humanized mouse model of EBV-
associated diseases involves the injection of EBV supernatant into a 
humanized mouse, thereby achieving in vivo infection. In our current 
approach, CD34+ HPCs were purified from the cord blood for the 
reconstitution of the humanized mouse. In parallel, BLCL was generated 
from the in vitro infection of B cells present in the CD34‒ fraction of the 
same cord blood sample. Upon the successful reconstitution of the 
human immune cells in the mouse, autologous BLCL was transplanted 
into its matching humanized mouse to generate a novel humanized 





 Figure 5.2: The de novo generation of human immune cells in the 
humanized mouse. Upon the injection of CD34+ HPCs from human cord 
blood, mice were kept for 12 weeks to allow the differentiation of human 
immune cells. Mice were then bled on week 12 to check for the 
percentages of chimerism (hCD45 versus mCD45). Human immune cells 
such as B cells (CD19+) and T cells (CD4+ and CD8+) were detected in 




 Figure 5.3: Profile of the human immune cells in the humanized mouse. 
Flow cytometric immunophenotyping was used to profile the reconstitution of 
human immune cells in the peripheral blood of the humanized mice. Mice were 
first bled at 12 weeks old (denoted as week 0) for the initial reconstitution 
check, followed by weekly facial bleeding till the age of 30 weeks old to monitor 
the changes in the percentages of human immune cells. (A) A general trend of 
declining chimerism (%hCD45+ cells) was observed in all humanized mice. (B 
and C) Within the CD45+ cells, B cells (%) declined inversely to the increased 
T cells (%). (D-F) Rising CD4/CD8 ratio indicated the increasing percentage of 
CD4+ T cells (over CD8+ T cells) across 18 weeks. Values are expressed as 








Figure 5.4: Body and spleen weight of humanized mouse injected with 
autologous BLCL. (A) Mice were euthanized at the end of 18 weeks with 
spleens harvested and expressed in microgram (mg). No significant (ns) 
difference in the spleen weight was noted between humanized mice injected 
with BLCL and its control (p = 0.3362). (B) Mice were weighed on a weekly 
basis. Body weight of mice was expressed as a percentage over the weight on 
day 1 (current weight/weight on day 1)*100. Humanized mice with autologous 
BLCL injected displayed lesser weight gain as compared to control mice 





5.3 Fetal liver as an alternative source of CD19+ B cells for BLCL 
generation 
 
With the success of utilizing cord blood to generate an autologous 
humanized mouse model, we proceeded to recapitulate this model 
using the fetal liver. This is because the fetal liver can provide a greater 
number of CD34+ HPCs for the reconstitution of a larger cohort of 
humanized mice. We employed an identical approach as depicted in 
Figure 5.1 to obtain BLCL from CD34‒ fraction of the fetal liver. 
However, in vitro EBV infection of this fraction failed to generate any 
BLCL.  
 
To increase the possibility of establishing BLCL from the fetal liver 
CD34‒ fraction, cells were sorted for CD19 to obtain a highly purified 
population of B cells for in vitro EBV infection. In the CD19+ fraction, 
cells were positive for CD45 and CD19, but negative for CD3, CD4, 
and CD8 (Figure 5.5, first row). On the other hand, a mixture of B cells 
and T cells were observed in the unsorted fraction (Figure 5.5, last 
row). Despite the enrichment of CD19+ B cells, the formation of 
macroscopic cell clumps was not observed and BLCL generation using 




Figure 5.5: CD34‒ fraction of fetal liver as a source of B cells for BLCL 
generation. The CD34‒ fraction obtained after CD34+ HPCs isolation process 
was further sorted for CD19+ B cells (Top row). In the CD19+ fraction, cells 
were confirmed to be positive for CD19 and CD45, but negative for CD3, CD4 
and CD8. EBV supernatant was added into each of the three fractions (CD19+ 




5.4 Fetal bone marrow and fetal spleen as alternative sources of 
CD19+ B cells for BLCL generation 
 
With the inability to generate BLCL from the fetal liver CD34‒ fraction, 
we next explored the usage of fetal bone marrow and fetal spleen as 
alternative sources of B cells for BLCL generation. Based on the CD19 
and CD45 staining, the presence of unwanted CD45‒CD19‒ cells, 
which can hinder the efficiency of EBV, was observed to be in excess 
in all three fetal liver samples (Figure 5.6). More importantly, a notably 
higher percentage of CD45+CD19+ cells were observed in the fetal 
bone marrow (16.9% and 51.8%) and fetal spleen (43.4% to 62.1%), 
indicating a greater abundance of B cells for EBV infection.  
 
As the B cells from fetal bone marrow and fetal spleen are 
developmentally and immunophenotypically distinct, the 
characterization of these B cells from these two lymphoid organs was 
necessary to elucidate their immunophenotypes prior to EBV infection 
and BLCL generation. As seen in Figure 5.7A, an average of 85% and 
95% B cell purity was obtained for the CD19-sorted fetal bone marrow 
and spleen respectively.  
 
Based on the comparison of cell surface markers, we observed 
distinctive differences in the immunophenotypes of B cells from the 
fetal bone marrow and fetal spleen (Figure 5.7A). A notable higher 
numbers of CD34+ cells (hematopoietic progenitor cell marker) were 
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found in the fetal bone marrow, coherent with the presence of HPCs in 
the bone marrow for hematopoiesis. 
 
When we gated on the CD19+ B cells from fetal bone marrow and fetal 
spleen, a further distinction in CD10, IgM, and IgD expressions were 
observed. In the fetal bone marrow, the majority of the CD19+ B cells 
were CD10+IgM‒IgD‒, exhibiting surface markers of pro- and pre-B cell 
stage, illustrating the process of early B cell differentiation in the bone 
marrow. In comparison, a majority of the CD19+ B cells in the fetal 
spleen, a secondary lymphoid organ, displayed a CD10‒IgM+IgD+ 
profile. This observation is in agreement with B cell development, 
where the loss of CD10 expression is accompanied by the gain of IgM 
and IgD expressions when B cells mature and migrate into the 
periphery.  
 
In view of the progressive maturation of B cells, the decline of CD10 
expression alongside with the increase of CD20 and CD45 expressions  
were well-illustrated in the CD19+ B cells of the fetal spleen, displaying 
a higher expressions of CD20 and CD45 as compared to the CD19+ B 
cells of the fetal bone marrow (Figure 5.7B) [224-226]. Cells from both 










Figure 5.6: Comparison of the C19+CD45+ cells between fetal liver CD34‒ 
fraction, fetal bone marrow, and fetal spleen. Owing to the inability to 
generate BLCL from the CD34‒ fraction of the fetal liver, fetal bone marrow and 
fetal spleen were explored as alternative sources of B cells. Based on 
C19+CD45+ gating, a low percentage of B cells (2.37% to 3.92%) was observed 
in the fetal liver. This was in contrast to the fetal bone marrow (16.9% and 
51.8%) and fetal spleen (43.4% to 62.1%), which indicated a greater 







Figure 5.7: Characterization of CD19+ B cells in the fetal bone marrow and 
fetal spleen. Flow cytometric immunophenotyping of B cells in the fetal bone 
marrow and fetal spleen was performed prior to in vitro EBV infection. A portion 
of cells from the fetal bone marrow and fetal spleen was further sorted for 
CD19 and presented alongside. (A) The majority of the CD19+ B cells in the 
fetal bone marrow were CD10+IgM‒IgD‒, while cells from the fetal spleen were 
mostly CD10‒IgM+IgD+. (B) B cells from the fetal spleen displayed higher 
expression of CD45 and CD20 than those of the fetal bone marrow. All cells 





5.5 Characterization of the fetal-derived BLCLs  
 
Regardless of the immunophenotypic differences between CD19+ cells 
from the fetal bone marrow and fetal spleen, BLCLs were successfully 
established from both samples. As early as day 29, the formation of 
macroscopic cell clusters characteristic of B cell immortalization and 
BLCL establishment were observed in both unsorted and CD19-sorted 
fetal bone marrow and fetal spleen samples (Figure 5.8A). While 
BLCLs were generated from all the fractions, higher efficiency and 
faster outgrowth of BLCLs were observed in the unsorted fractions of 
fetal bone marrow and fetal spleen (Figure 5.8B).  
 
Despite the fact that fetal bone marrow and fetal spleen are two 
different compartments for B cell development, BLCLs generated from 
these two samples displayed similar immunophenotype. As shown in 
Figure 5.9, fetal-derived BLCL demonstrated negative staining for non-
B cell markers such as CD3, CD4, CD8, and CD56 
(CD3‒CD4‒CD8‒CD56‒). Furthermore, these BLCLs were not stained 
for developmental-specific B cell markers such as CD5, CD10, CD23, 
CD27, and CD138 (CD5‒CD10‒CD23‒CD27‒CD138‒).  
 
These cells were stained for pan-B cell markers such as CD19 and 
CD20 (CD19+CD20+), along with the detection of co-stimulatory 
markers such as CD40, CD86, and HLA-DR (CD40+CD86+HLA-DR+). 
Staining revealed that BLCLs generated from the unsorted and CD19- 
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sorted spleen fractions had indistinguishable immunophenotype 
(Appendix F). 
 
During EBV infection, the upregulation of CD95 is observed on B cells 
as the result of EBV LMP1 expression [214-216].  Indeed, we observed 
the expression of CD95 in these fetal-derived BLCLs and immunoblot 
in Figure 3.12 further confirmed the presence of EBV latent proteins - 
EBNA-1, LMP1, and EBNA-2. Importantly, the detection of EBNA-2, 
which is uniquely found in PTLD patients and BLCLs, confirmed that 
these fetal-derived BLCLs were expressing the latency III program 
(Table 1.1).  
 
With the successful establishment of BLCLs from the fetal bone 
marrow and fetal spleen, these cells were tested for their staining with 
α-EBV TCR-like mAbs. As shown in Figure 5.10, staining was 
observed with α-EBNA-1 TCR-like mAb on HLA-A*02 fetal-derived 
BLCL but not non-HLA-A*02 fetal-derived BLCL. Modest staining was 
also seen with α-LMP1 TCR-like mAb, consistent with the observation 
of EBNA-1 pMHC > LMP1 pMHC as described earlier with the PBMC-
derived BLCLs in Figure 3.13. These data demonstrated that the fetal-
derived BLCLs not only expressed surface markers and EBV latent 
proteins akin to that of EBV-infected B cells in humans, they also 





 Figure 5.8: Establishment of BLCLs from both fetal bone marrow and 
fetal spleen. Regardless of the immunophenotypic differences between the 
CD19+ B cells harvested from the fetal bone marrow and fetal spleen, 
successful BLCL establishment was achieved with both fetal organs. (A) The 
formation of macroscopic colonies was detected at day 29. (B) BLCLs 
established from the unsorted fetal bone marrow and fetal spleen displayed 
faster outgrowth as compared to those generated from the CD19-sorted 
fractions. (+) indicates the relative amount of BLCL outgrowth based on 






Figure 5.9: Immunophenotype of BLCL generated from fetal samples. Upon
in vitro EBV infection and immortalization of B cells from the fetal samples (bone 
marrow and spleen), stable BLCL capable of indefinite proliferation was 
established. Flow cytometric immunophenotyping was performed to characterize 
the BLCL based on their expression of surface markers. BLCL generated from 
fetal bone marrow and fetal spleen expressed similar immunophenotype, with no 
staining observed for non-B cell markers such as CD3, CD4, CD8, and CD56. B 
cell differentiation markers such as CD5, CD10, CD23, CD27, and CD138 were 
also absent. These cells were verified as BLCL based on their surface 
expression of CD45, CD19, and CD20. The expression of EBV latent proteins 
(Figure 3.12) confirmed the presence of EBV. Additionally, the 
immunophenotype of BLCL generated from unsorted fraction spleen was also 
found to be indistinguishable from those generated from the CD19-sorted 





 Figure 5.10: Detection of surface EBNA-1 and LMP1 pMHC on BLCLs 
generated from fetal samples. Staining with α-EBNA-1 TCR-like mAb and α-
LMP1 TCR-like mAb were performed on HLA-A*02 and non-HLA-A*02 fetal 
BLCLs. Staining with both antibodies were observed in HLA-A*02 fetal BLCL 
but not on the non-HLA-A*02 fetal BLCL. Higher staining was observed with 
the α-EBNA-1 TCR-like mAb as compared to α-LMP1 TCR-like mAb, 
consistent with the staining observed with PBMC-derived BLCLs (Figure 3.13).  
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5.6 Improving human immune cells reconstitution in the 
autologous humanized mouse model  
 
With the successful establishment of an autologous humanized mouse 
model, this model could serve as a platform to evaluate the therapeutic 
efficacy and toxicity of novel therapeutics such as α-EBNA-1 TCR-like 
mAb. This model could further be utilized to elucidate the roles of 
humoral (antibody) effector cells such as monocytes/macrophages, 
dendritic cells and NK cells in mediating the therapeutic effects. To 
enable the determination of antibody treatment effects and 
mechanisms, we sought to boost the reconstitution of these human 
immune cells in our autologous humanized mice via HDI of plasmids 
encoding human IL-15 and FLT3L, a technique employed by Qingfeng 
et al. (Figure 5.11) [198]. 
 
Mice were hydrodynamically injected with respective plasmids at week 
13 post-humanization and their peripheral blood was checked for 
human immune cells reconstitution from week 14 to 17. While the 
increased in CD11c+ a cell (dendritic cells) was observed at weeks 14 
and 15, this enhancement was not found to be statistically significant 
(Figure 5.12A and B). On the other hand, no augmentation of the 
CD14+ cells (monocytes/macrophages) reconstitution was noted 




In contrast, the analysis of CD56+ and NKp46+ expression in the 
peripheral blood revealed an enhancement of NK cell percentages 
upon HDI (Figure 5.13). Representative mice with similar NK cells 
reconstitution at week 12 were compared to illustrate the augmentation 
of these CD56+NKp46+ NK cells (Figure 5.13A and C). The 
enhancement of CD56+ and NKp46+ cells reconstitution were observed 
at weeks 14 and 15, before returning to levels similar to that of 
untreated humanized mice at week 16 (Figure 5.13B and D). Taken 
together, we have demonstrated that HDI can improve the 
reconstitution of the human NK cells in the autologous humanized 





Figure 5.11: Improving the human immune cells reconstitution in the 
humanized mice. Schematic illustration of using HDI of plasmids encoding 
human IL-15 and FLT3L to boost the human immune cells reconstitution in the 
humanized mouse injected with autologous BLCL. Fetal liver CD34+ HPCs-
reconstituted humanized mice were bled at week 12 for chimerism check 
(hCD45 versus mCD45). At week 13, HDI of plasmids encoding IL-15 and 
FLT3L was performed. Thereafter, weekly facial bleeding was conducted to 
check for the percentages of CD56, NKp46, CD11c, and CD14 reconstitution in 
the peripheral blood of mice. The injection of autologous BLCL (established 





Figure 5.12: Effects of HDI on the reconstitution of CD11c+ and CD14+ 
cells. Percentages of CD11c+ and CD14+ cells were obtained via multicolour 
flow cytometric analysis of the mouse peripheral blood. (A and C) Flow 
cytometry plot showing the percentages of CD11c and CD14 before (at week 
12) and after (at week 14) hydrodynamic injection of plasmids encoding IL-15 
and FLT3L. (B and D) CD11c+ (%) and CD14+ (%) from week 12 to 17. 
Although an increased reconstitution of CD11c+ cells was observed at week 14 
and 15, the effect was not statistical significant. No enhancement in CD14+ 





Figure 5.13: Effects of HDI on the reconstitution of CD56+ and NKp46+ 
cells. Percentages of CD56+ (%) and NKp46+ (%) cells were obtained via 
multicolour flow cytometric analysis of the mouse peripheral blood. (A and C) 
Flow cytometry plot showing the percentage of CD56 and NKp46 before (at 
week 12) and after (at week 14) hydrodynamic injection of plasmids encoding 
IL-15 and FLT3L. (B and D) CD56+ (%) and NKp46+ (%) from week 12 to 17. 
There was a statistical significant enhancement of CD56+ cells reconstitution at 
week 14 (p = 0.0036) and week 15 (p < 0.0001). A similar observation was also 
noted for NKp46+ cells reconstitution at week 14 (p = 0.0014) and week 15 (p = 















Chapter 6:  






Epstein-Barr virus, the ubiquitous gammaherpesvirus is associated 
with a large number of human malignancies of epithelial and lymphoid 
origins. As a common antigen found in both lytic and latent phases of 
EBV infection, EBNA-1 plays crucial roles in viral genome maintenance, 
immunoevasion, and possibly EBV-oncogenesis. As such, there has 
been a long-standing interest in targeting EBNA-1 as a means to 
attenuate EBV infection and tumorigenesis in EBV-associated diseases. 
However, targeting EBNA-1 was deemed impractical as various studies 
in the early 1990s reported that the GAr within the EBNA-1 protein 
could auto-inhibit its degradation, thereby reducing its peptide 
presentation to T cells and consequently impairing EBNA-1-specific T 
cell responses.  
 
Consistent with earlier reports, we showed that the deletion of GAr in 
E1ΔGA construct resulted in the increased expression of EBNA-1 
protein [18, 204]. While previous studies utilized fusion proteins and 
non-viral epitopes such as ovalbumin (SIINFEKL), GFP, p53 and IĸBα 
as the epitope reporters for EBNA-1 presentation, these read-outs 
might not reflect how EBNA-1 is naturally processed and presented. 
This is because these fusion partners can potentially affect the rate and 
fidelity of EBNA-1 protein synthesis, folding, transport, degradation, 
and presentation [227]. As an alternative to the usage of fusion 
partners, we employed the 2A sequences to achieve equimolar 
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translation of GFP and WT EBNA-1 or E1ΔGA, thereby overcoming the 
problems associated with the use of fusion proteins. With these 
constructs, we further confirmed that the presence of GAr not only 
affected EBNA-1 expression but also reduced GFP synthesis, 
substantiating the role of GAr in mediating viral evasion mechanism by 
reducing protein synthesis. 
 
In 2004, three landmark publications reshaped the paradigm of EBNA-
1 presentation with the suggestion that EBNA-1-specific T cells could 
be detected in vivo and that, EBNA-1 peptides could be generated for 
presentation to T cells through defective ribosomal products – 
erroneous EBNA-1 protein derivatives from the translational machinery 
[56-58].  The processing and presentation of EBNA-1 protein for T cell 
priming were further validated based on the detection of both EBNA-1-
specific CD4 and CD8 T cells in healthy EBV-seropositive individuals 
[48, 56, 57, 228, 229]. These studies affirmed that EBNA-1 
presentation is indeed naturally occurring.   
 
Based on the observation of EBNA-1-specific T cells, we interrogated 
the ability of our in-house produced, EBNA-1-specific antibody (α-
EBNA-1 TCR-like mAb) to distinguish the presentation of EBNA-1 
epitope between WT EBNA-1 and E1ΔGA-transfectants. However, we 
were unable to detect EBNA-1 peptide (FMVFLQTHI)-MHC complexes 




The lack of staining on HEK293T transfectants with α-EBNA-1 TCR-
like mAb could be attributed to the inability of the antibody to bind to 
surface EBNA-1 pMHC or the absence of these surface complexes.  
However, we have excluded the possibility that our antibody is 
incapable of staining surface pMHC complexes because its specificity 
has been verified by various experimental techniques such as pMHC 
ELISA, peptide pulsing, and direct staining of surface EBNA-1 pMHC 
on BLCLs. While we did not address why surface EBNA-1 pMHC were 
not detected in EBNA-1-transfectants, one possibility could be that the 
forced expression of a non-native EBNA-1 protein in cells (HEK293T 
and HeLa) which are not the natural hosts of EBV might compromise 
the natural generation of a processed and unaltered epitope 
(FMVFLQTHI) detected by α-EBNA-1 TCR-like mAb. Nonetheless, 
EBNA-1 epitopes could be measured via mass spectrometry-based 
approaches to evaluate the full profile of presented peptides, though 
this would require the optimization of surface peptide elution strategies 
[230, 231]. Still, it is encouraging that α-EBNA-1 TCR-like mAb could 
detect the presentation of surface EBNA-1 pMHC on the B cells latently 
infected with EBV (BLCLs), demonstrating the availability of EBNA-1 as 
a therapeutic target.  
 
With the observation that α-EBNA-1 TCR-like mAb could detect the 
presentation of the endogenous EBNA-1 epitope on BLCLs, we set out 
to investigate whether this antibody could be used to target EBV-
infected cells. Based on the surface plasmon resonance data 
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previously reported by our laboratory, and the pMHC ELISA data 
presented here, we showed that α-EBNA-1 TCR-like mAb has 
excellent binding characteristics, with affinity and avidity profiles in the 
nanomolar range [129].  
 
We further demonstrated that staining with α-EBNA-1 TCR-like mAb 
was only observed on HLA-A*02 BLCLs, but not on PBMC from which 
this BLCL was generated, highlighting its specificity in detecting 
surface EBNA-1 pMHC presented by these EBV-infected cells. Equally 
encouraging, we were able to detect constitutive surface presentation 
of the EBNA-1 pMHC with α-EBNA-1 TCR-like mAb on several donor-
derived BLCLs, illustrating the feasibility of targeting surface EBNA-1 
pMHC with our antibody.   
 
We next employed a mouse xenograft model with HLA-A*02 BLCL 
injected into NSG mice as a means to evaluate the in vivo therapeutic 
effect of α-EBV TCR-like mAb. As NSG mice are devoid of a functional 
adaptive immune system, the injection of EBV-infected BLCL and their 
subsequent unrestricted proliferation in mice is analogous to 
immunosuppressed humans developing B cell lymphoproliferative 
disorder. As BLCL derived from different donors are heterogeneous in 
their immunophenotypes and their growth rates, the employment of this 
mouse xenograft model can potentially capture and reflect 




In this model, successful engraftment of BLCL was evident as early as 
day 7 post-injection of the BLCL. Severe disease manifestations were 
observed in the spleens, livers, and kidneys when these mice were 
monitored over a longer period to study disease progression. The 
administration of α-EBNA-1 TCR-like mAb resulted in delayed weight 
loss and prolonged survival in these mice. Surprisingly, this therapeutic 
effect was not observed in mice given the α-LMP1 TCR-like mAb, 
despite this antibody displaying a higher binding affinity as compared to 
α-EBNA-1 TCR-like mAb [129].  
 
A possible reason for the therapeutic effect observed with the α-EBNA-
1 TCR-like mAb could be due to a greater availability of surface EBNA-
1 pMHC for antibody binding, correlating to the flow cytometry data 
where α-EBNA-1 TCR-like mAb displayed a stronger staining profile 
compared to the α-LMP1 TCR-like mAb (Figure 3.13). This could 
suggest that, while the binding avidity of an antibody is critical, the 
surface availability/epitope density might be an equally important factor 
in determining the therapeutic efficacy of an antibody. The significance 
of surface epitope density has been illustrated by FDA-approved anti-
human epidermal growth factor receptor 2 (HER2) antibody, where 
patients with a higher score of HER2 overexpression on tumors 
displayed a better treatment outcome [232]. Therefore, surface 
availability of pMHC for TCR-like mAb binding has to be included as a 
factor when designing treatment modalities with this type of antibody.  
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When organs of the α-EBNA-1 TCR-like mAb-treated mice were 
examined, amelioration of disease was observed in the livers and 
spleens but not in the kidneys. Furthermore, an increasing BLCL 
infiltration was seen in the kidneys at later time points, possibly 
providing an explanation as to how all the mice succumbed to the 
disease. To understand the underlying mechanisms of α-EBNA-1 TCR-
like mAb treatment, a series of in vitro assays were performed. 
Antibodies have been shown to mediate an array of effector functions 
such as the direct induction of apoptosis, CDC, and ADCC [123, 125, 
132-135]. We showed that α-EBNA-1 TCR-like mAb treatment in vitro 
could trigger early apoptosis and promote antibody-mediated 
phagocytosis. While the ability to mediate direct apoptosis has been 
ascribed to similar antibody-based therapeutic modalities [124, 134], 
our group is the first to provide evidence on the dual functionalities of 
TCR-like mAbs in promoting early apoptosis, as well as enhancing the 
phagocytosis of tumor cells. It would be of interest to evaluate whether 
the α-EBNA-1 TCR-like mAb could additionally perform CDC and 
ADCC in vitro as well as in vivo. Nonetheless, the dual functionalities of 
α-EBNA-1 TCR-like mAb in mediating both immune effector-dependent 
and -independent functions that we demonstrated here, are favorable 
to its consideration as a therapeutic candidate.  
 
In the recent years, immunotherapy has gained increasing international 
attention for its utility in cancer treatment. An example is the successful 
application of anti-CD20 antibody (rituximab) in PTLD treatment. As 
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one of the most effective forms of treatment, rituximab clearly 
demonstrates the feasibility of antibody-based approach in PTLD 
treatment, but there are unwanted side-effects based on its use in 
PTLD patients [105, 106]. The use of rituximab has not only been 
shown to increase the chance of opportunistic infection but also to 
promote the development of CD20‒ lymphoma refractory to rituximab 
treatment [102, 103]. The depletion of healthy CD20-expressing B cells 
can moreover be detrimental to the already immunosuppressed graft 
recipients and this outcome is counterproductive as humoral responses 
are crucial for long-term host immunity.  
 
The α-EBNA-1 TCR-like mAb we present here exhibits the ability to 
differentiate EBV-infected cells from the uninfected cells, offering an 
advantage over the pan-B cell depletion engendered by rituximab 
treatment. At the same time, given the common expression of EBNA-1 
in all EBV-associated malignancies of varying latency programs, the 
use of this antibody might further enable the targeting of EBNA-1-
expressing cells in different EBV-associated diseases. As a novel class 
of immunotherapeutics, the α-EBNA-1 TCR-like mAb we detail here is 
the first-of-its-kind that has been evaluated for its therapeutic function 
in a murine model of EBV-PTLD.  
 
In an up-and-coming therapy for PTLD, allogeneic EBV-specific T cells 
are isolated from donors and injected into PTLD patients [114-120]. 
However, the generation and employment of adoptive T cell therapy 
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often involve a significant time delay and require technical expertise. 
This limits its widespread application and its availability in urgent 
clinical settings. The prospect of this approach is further complicated 
by the high degree of stringency required for HLA-compatibility to avoid 
graft-versus-host disease and the propensity of disease complications 
arising from donor-derived pathogens such as cytomegalovirus.    
 
The TCR-like mAb we describe here binds to surface EBNA-1 pMHC in 
a manner similar to how EBV-specific T cells recognize their targets 
(EBV-infected cells).  As an antibody, α-EBNA-1 TCR-like mAb has 
advantages in that it can be produced in large quantities and utilized in 
clinical settings where adoptive T cell therapy is not practical. In 
addition, these antibodies are ‘immune’ to the immunosuppressive 
tumor microenvironment which can regulate T cell function [132]. 
Finally, as EBNA-1 is expressed in EBV latency programs I, II and III, 
the utility of α-EBNA-1 TCR-like mAb is not restricted to latency III-
expressing PTLD but can also be extended to treat EBV-associated 
diseases of other latency programs.   
 
The α-EBNA-1 TCR-like mAb we report here is a mouse-derived 
antibody, and thus it is not suitable for application in humans in its 
current form as its administration can lead to the generation of a 
human anti-mouse antibody response. This response can lead to the 
development of allergic reactions such as fever, chills, anaphylaxis, 
urticaria and hypotension [233-237]. Moreover, these human anti-
 161 
 
mouse antibodies can form immune complexes with the mouse-derived 
antibody, attenuating the therapeutic efficacy of treatment [238-241]. 
As such, current efforts from our laboratory focus on generating a 
humanized antibody variant of the α-EBNA-1 TCR-like mAb. While the 
conversion of mouse-derived α-EBNA-1 TCR-like mAb is underway, we 
have developed a novel humanized mouse model of EBV-PTLD 
compatible for the preclinical evaluation of α-EBNA-1 TCR-like mAb.  
 
Our approach is based on the humanized mouse model of EBV 
infection. In the conventional modeling of EBV infection, EBV 
supernatant is injected into the humanized mice, establishing an in vivo 
EBV infection of the reconstituted human B cells. Here, we present a 
novel transplantable tumor model in which autologous BLCL generated 
in vitro is injected into humanized mouse reconstituted with CD34+ 
HPCs derived from the same donor. In this model, we have validated 
the expression of latency III program in BLCL before transplanting 
them into the humanized mice (Figure 3.12).  
 
BLCLs are the in vitro counterpart of B cells found in EBV-PTLD 
patients, both bearing the latency III expression pattern, justifying the 
biological relevance of using BLCL to model EBV-PTLD. The use of 
BLCL also provides convenience, as cells can be maintained in culture 
and made readily available. These cells can be characterized and 
assayed for their responses to therapeutic candidates in vitro prior to in 
vivo evaluation. The use of BLCL also offers added advantage over the 
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injection of virus supernatant in the conventional modeling as the virus 
titer does not equate to infectivity. In this regard, the employment of 
BLCL offers a more quantitative control over the desired tumor load, 
allowing a more precise control of the disease outcome as compared to 
the use of a virus supernatant. 
 
In terms of establishing an in vivo model of EBV-PTLD, our approach 
encompasses both orthotopic and syngeneic facets of animal modeling. 
As BLCL is intravenously injected into mice, they are transplanted onto 
an appropriate anatomical setting similar to that of PTLD in humans. 
With both BLCLs and HPCs derived from the same donor (autologous), 
they have the identical genetic background, thus eliminating a 
possibility of immunological rejection due of HLA-incompatibility. 
 
We have successfully generated an autologous humanized mouse 
model and delineated the human immune cells that reconstitute using 
samples derived from human cord blood. However, due to the limited 
availability of CD34+ HPCs in cord blood, the reconstitution of 
humanized mice is often restricted to 4-5 mice per single unit of cord 
blood, leading to the lack of statistical power required for studies. We 
therefore switched to the usage of the human fetal liver as it provides a 
greater number of CD34+ HPCs for generating a large cohort of 
humanized mice. We have further demonstrated that both fetal bone 
marrow and fetal spleen can provide a good source of B cells for BLCL 
generation and showed that BLCLs generated from both lymphoid 
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organs were indistinguishable. Encouragingly, these fetal-derived 
BLCLs were stained positive for surface EBNA-1 pMHC (Figure 3.10), 
providing an important indication that our autologous humanized 
mouse model may function as a valuable platform for the future 
evaluation of α-EBNA-1 TCR-like mAb.  
 
While we have successfully developed an autologous humanized 
mouse model, this model required additional refinements. This is 
because cells such as dendritic cells, monocytes/macrophages, and 
NK cells are poorly reconstituted and not well-studied in the humanized 
mouse [190-192]. As these cell types are important immune effectors in 
antibody therapy and the availability of these cells in the humanized 
mouse would impact the outcome of antibody treatment. It was 
therefore important to determine and improve the reconstitution of 
these cells.  
 
To enhance the reconstitution of the relevant immune cells, we 
performed HDI of plasmids encoding for human IL-15 and FLT3L into 
humanized mice. While no enhancements of dendritic cells and 
macrophages were observed, a significant augmentation of NK cells 
reconstitution was detected for two consecutive weeks (Figure 5.13). 
Here, we have demonstrated that HDI is a practical and cost-effective 
approach in the transient augmentation of specific immune cells in the 




With the information on the specific cell types responding to the HDI as 
well as the kinetics of the enhancement, subsequent work can be 
focused on exploring the necessity of a maintenance boost and the 
utility of other cytokine-expressing plasmids to achieve a more robust 
platform for antibody evaluation. 
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6.2 Future perspectives 
 
We have demonstrated that the α-EBNA-1 TCR-like mAb in its native 
IgG1 format was capable of eliciting an observable therapeutic effect in 
BLCL-engrafted NSG mice. It would be of interest to evaluate whether 
different isotypes and subclasses of the antibody can elicit better 
effector functions. Currently, a humanized variant of the α-EBNA-1 
TCR-like mAb is under development, and in due course the evaluation 
of its therapeutic efficacy, pharmacodynamics, pharmacokinetics or 
toxicology will be conducted. Additionally, functional analysis of 
different immune cell types can be studied by using cell-specific 
immunodepletion to dissect the role of each cell type in the humanized 
mouse in mediating α-EBNA-1 TCR-like mAb treatment effects.   
 
Besides the humanization of α-EBNA-1 TCR-like mAb, the future 
modification can encompass the conjugation of recombinant 
immunotoxins or cytokines to enhance its cytotoxicity in PTLD 
treatment. Another area that can be further explored to enhance 
therapeutic efficacy is the conversion of α-EBNA-1 TCR-like mAb into a 
bispecific T cell engager [242, 243]. These antibodies combine the 
specificity of two antibodies, with one arm of the antibody specific for 
the EBNA-1 pMHC, and the other arm specific for CD3+ T cells. In this 
manner, the bispecific antibody of α-EBNA-1 TCR-like mAb can bind to 
EBV-infected cells, and at the same time draws T cells into proximity 




Multiple studies have looked into the synergistic effects of combinatory 
drug therapy in cancer treatments [219, 244]. In particular, rituximab 
and cyclophosphamide which are used to treat PTLD have 
demonstrated synergistic effects when delivered as a combinatory 
treatment in the treatment of other hematological malignancies. 
Prompted by such observations, the combinatory treatment of α-EBNA-
1 TCR-like mAb with current drugs can be investigated. Finally, our 
laboratory has also generated two other α-EBV TCR-like mAbs 
targeting LMP1 and LMP2A (α-LMP1 TCR-like mAb and α-LMP2A 
TCR-like mAb). It would be of interest to determine if a combinatory 
treatment of all three TCR-like mAbs may engender any form of 






































































Appendix E: α-EBNA-1 TCR-like mAb ameliorated disease manifestations 




Appendix F: immunophenotype of BLCLs generated from the unsorted and 
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